<!DOCTYPE html>


<style>
    body{
  background: #18181B;
}

.main{
  font-family: "Noto Sans", ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Noto Color Emoji";
  color: #FDFDFD;
}

h1 {
  font-size: 2.5rem;
  color: white;
}

h3 {
  font-size: 1.5rem;
  background: #0c087c;
  padding: 10px;
  margin: 0px;
  border: 1px solid #6b7280;}

.extended-title{
  width:100%;
}

#gsk-overview{
  display:flex;
}

h4 {
  font-size: 1rem;
  background: #27272A;
  padding: 10px;
  margin: 0px;
  border-bottom: 1px solid #6b7280;
}

h2 {
  font-size: 1.5rem;
  margin-top: 3px;
  color:#000000;
}

.header{
  display: flex;
  justify-content: center;
  align-items: center;
}
.header > * {
  margin-inline: 20px;
}

.flex-row {
  display: flex;
  flex-direction: row;
  padding:10px;
  border: 1px solid #27272A;
}

.flex-row>div {
  flex: auto;
  box-sizing: border-box;
  display: flex;
  flex-direction: column;
  justify-content: center;
  align-items: center;
}

progress[value] {
  --background: #6D6D6D;
  -webkit-appearance: none;
  -moz-appearance: none;
  appearance: none;
  border: none;
  height: 4px;
  margin: 0 10px;
  border-radius: 10em;
  background: var(--background);
}

progress[value]::-webkit-progress-bar {
  border-radius: 10em;
  background: var(--background);
}

progress[value]::-webkit-progress-value {
  border-radius: 10em;
  background: var(--color);
}

progress[value]::-moz-progress-bar {
  border-radius: 10em;
  background: var(--color);
}

label {
  font-size: 20px;
  font-weight: bold;
  display: block;
  margin: 20px 0;
}

.tab {
  overflow: hidden;
  border: 1px solid #27272A;
  background-color: #27272A;
}

.tab button {
  background-color: inherit;
  float: left;
  border: none;
  outline: none;
  cursor: pointer;
  padding: 14px 16px;
  transition: 0.3s;
  color: #ffffff;
  font-size:1.2rem;
}

.tab div {
  background-color: inherit;
  float: left;
  border: none;
  outline: none;
  cursor: pointer;
  padding: 14px 16px;
  transition: 0.3s;
  color: #ffffff;
  font-size: 1.2rem;
}

.tab button:hover {
  background-color: #18181B;
}

.tab-title{
  font-size: 1.5rem;
  font-weight: bold;
  margin-bottom:-5px;
}

.tab button.active {
  background-color: #18181B;
  border-top: 1px solid #6b7280;
  border-bottom: 1px solid #18181B;
  border-left: 1px solid #6b7280;
  border-right: 1px solid #6b7280;
}

.tabcontent {
  display: none;
  padding: 6px 12px;
  background: #18181B;
  border: 1px solid #27272A;
  border-top: 1px solid #6b7280;
  margin-top: -2px;
}

#gsk-advice {
  display: flex;
  justify-content: center;
}

#gsk-metrics{
  width:100%;
}

#recommendation {
  margin-top: 20px;
  padding: 20px;
  border-radius: 10px;
  background-color: #e1ce86;
  color: #27272A;
  width:95%;
  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;
  font-size: 12pt;
}

.separator {
  margin: 20px 0;
}

.separator-border {
  margin: 20px 0;
  border-bottom: 1px solid #6b7280;
}

#gsk-rag{
  margin: 32px 28px;
  padding: 12px 24px;
  background-color: #111516;
}

.section-container {
  margin-bottom: 32px;
}

  .components-container {
    display: flex;
    flex-flow: row wrap;
    align-items: flex-start;
    gap: 0 32px;
  }

    .component-card {
      background-color: #14191B;
      border-radius: 16px;
      padding: 28px 32px 32px 32px;
      display: flex;
      flex-flow: column;
      align-items: center;
      margin-top: 32px;
      flex-grow: 1;
    }

    .component-title {
      font-size: 12px;
      font-weight: 500;
      color: #B1B1B1;
      padding-bottom: 8px;
    }

    .component-value {
      font-size: 32px;
      font-weight: 500;
      padding-bottom: 12px;
    }
      
      .text-green {
        color: #04B543;
      }
      
      .text-orange {
        color: #E76E0F;
      }
      
      .text-red {
        color: #EA3829;
      }

      .tooltip {
        position: relative;
        display: inline-block;
      }

      .tooltip .tooltiptext {
        visibility: hidden;
        width: 120px;
        background-color: #464646;
        color: #E6E6E6;
        text-align: center;
        border-radius: 6px;
        position: absolute;
        z-index: 1;
        top: 150%;
        left: 50%;
        margin-left: -60px;
        font-size: 12px;
        padding: 12px;
      }
      
      .tooltip .tooltiptext::after {
        content: "";
        position: absolute;
        bottom: 100%;
        left: 50%;
        margin-left: -5px;
        border-width: 5px;
        border-style: solid;
        border-color: transparent transparent black transparent;
      }
      
      .tooltip:hover .tooltiptext {
        visibility: visible;
      }

    .overall-card {
      background-color: #026836;
      border-radius: 16px;
      padding: 28px 32px 32px 32px;
      display: flex;
      flex-flow: column;
      align-items: center;
      justify-content: center;
      margin-top: 32px;
      flex-grow: 1;
    }
  
    .overall-title {
      font-size: 12px;
      font-weight: 500;
      color: #E6E6E6;
      padding: 14px 0 8px 0;
      text-transform: uppercase;
     }
  
    .overall-value {
      font-size: 32px;
      font-weight: 500;
      padding-bottom: 12px;
      color: #E6E6E6;
    }

.section-title {
  font-size: 12px;
  color: #B1B1B1;
  margin-bottom: 20px;
  text-align: left;
  width: 100%;
}

.section-content {
  color: #E6E6E6;
  font-size: 20px;
  line-height: 1.5;
}

.section-card {
  background-color: #14191B;
  border-radius: 16px;
  padding: 28px 32px 32px 32px;
  display: flex;
  flex-flow: column;
  align-items: center;
}

.correctness-indicator{
  padding: 20px;
  border-radius: 50px;
  font-size: 16pt;
  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;
  text-align: center;
}

.metric-title{
  margin: -2px;
  border-bottom: none;
}

.hist-row {
  display: flex;
  flex-direction: row;
  padding: 10px;
  justify-content: space-around;
  width: 85%;
}

.hist-row>div {
  flex: auto;
  box-sizing: border-box;
  display: flex;
  flex-direction: column;
  justify-content: center;
  align-items: center;
  padding-left: 1%;
  padding-right: 1%;
}

.tab-row{
  display: flex;
  flex-direction: column;
  align-items: center;
}

#component-table{
  width:50%;
  margin-top: 10px;
}

.green{
  background-color: #0a980a;
}

.orange {
  background-color: #e5b62a;
}

.red {
  background-color: #ba0e0e;
}

.progress-green {
  --color: #04B543;
}

.progress-orange {
  --color: #E76E0F;
}

.progress-red {
  --color: #EA3829;
}

.corr-plot{
  flex: 1;
  padding-left: 2%;
}

.tooltip-text {
  position: absolute;
  display: none;
  visibility: hidden;
  z-index: 1;
  top: 100%;
  left: 0%;
  width: 100%;
  color: white;
  font-size: 12px;
  background-color: #2d3d4c;
  border-radius: 10px;
  padding: 10px 15px 10px 15px;
}

#fade {
  opacity: 1;
  transition: opacity 0.5s;
}

#delay {
  opacity: 0;
  transition: opacity 0.2s;
  transition-delay: 1s;
}

td {
  position: relative;
}

tr:hover .tooltip-text {
  display: block;
  visibility: visible;
}

.tr:hover #fade {
  opacity: 1;
}

.tr:hover #delay {
  opacity: 1;
}

.callout {
  padding: 0.5rem 1rem 0.5rem 3rem;
  background: #D9EDF9;
  border: 3px solid #0088D1;
  color: #272eb5;
  position: relative;
  max-width: 40rem;
  border-radius: 10px;
  margin-top: 10%;
  font-size: 11pt;
}

.callout-icon {
  content: "";

  /* SVG via a data URI! */
  background-size: cover;
  width: 1.5rem;
  height: 1.5rem;
  display: block;
  position: absolute;
  left: 0.9rem;
  top: 1.1rem;
}

.callout-icon svg{
  fill: #016ca7;
}
.callout p+p {
  margin-top: 1em;
}

.callout a {
  color: #272eb5;
  font-weight: bold;
}

#gsk-logo {
  padding-top: 10px;
}
</style>
<script src="https://cdn.bokeh.org/bokeh/release/bokeh-3.3.4.min.js" integrity="sha384-5QIrjQuyo4I/x6DK/Sau33lcA3hT2TCZGr9vbk+2ebd7Da6FnR1amdM+9B5xOrSf" crossorigin="anonymous"></script>
<script src="https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.3.4.min.js" integrity="sha384-tXTWPp/bAKa+K9RPuXh7DNvye0Mv+P+6y4rAMVy+pWapsnXg9UG7g20WZ0N4i28A" crossorigin="anonymous"></script>





<div class="main">
    <div id="gsk-rag" class="dark:text-white dark:bg-zinc-800 rounded border border-gray-500">
        <div class="header border-b border-b-gray-500">
            
                <svg xmlns="http://www.w3.org/2000/svg" width="60" height="30" viewBox="0 0 30 15" fill="none" id="gsk-logo">
                    <path fill="#fff" fill-rule="evenodd"
                        d="M22.504 1.549a4.196 4.196 0 0 1 2.573-.887v.002a3.783 3.783 0 0 1 2.706 1.086 3.783 3.783 0 0 1 1.126 2.69 3.771 3.771 0 0 1-1.126 2.69 3.77 3.77 0 0 1-2.706 1.085l-4.794.011-2.533 3.467L8.203 15l2.881-3.335a9.829 9.829 0 0 1-4.663-1.68H3.185L0 7.163h3.934C4.263 3.165 8.187 0 12.96 0c2.24 0 4.489.696 6.175 1.909a7.423 7.423 0 0 1 1.882 1.919 4.194 4.194 0 0 1 1.487-2.28ZM7.05 3.249l3.91 3.915h1.505L7.89 2.584a7.773 7.773 0 0 0-.84.665Zm4.079-2.008 5.923 5.923h1.503l-6.086-6.087c-.45.023-.898.078-1.34.164ZM4.574 8.226h-1.77l.784.693h1.584a8.454 8.454 0 0 1-.598-.693Zm9.479 0H5.984c1.469 1.477 3.656 2.377 5.977 2.422l2.092-2.422Zm-2.458 4.472 5.492-1.902 1.878-2.569h-3.508l-3.862 4.47Zm10.361-5.552h3.265a2.714 2.714 0 0 0 1.747-4.648 2.711 2.711 0 0 0-1.888-.773 3.127 3.127 0 0 0-3.123 3.124v2.297Zm3.659-3.73a.677.677 0 1 1-.134 1.348.677.677 0 0 1 .134-1.348Z"
                        clip-rule="evenodd" />
                </svg>
            <h1>RAG Evaluation Toolkit</h1>
        </div>
        
        <div class="section-container">
            <div class="components-container">
                
                <div class="component-card">
                    <div class="component-title">GENERATOR</div>
                    <div class="component-value tooltip  text-orange ">
                        48.0%
                            <span class="tooltiptext" id="fade">The Generator is the LLM inside the RAG to generate the answers.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=48.0 class=" progress-orange ">48.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">RETRIEVER</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The Retriever fetches relevant documents from the knowledge base according to a user query.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">REWRITER</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The Rewriter modifies the user query to match a predefined format or to include the context from the chat history.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">ROUTING</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The Router filters the query of the user based on his intentions (intentions detection).</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">KNOWLEDGE_BASE</div>
                    <div class="component-value tooltip  text-green ">
                        78.79%
                            <span class="tooltiptext" id="fade">The knowledge base is the set of documents given to the RAG to generate the answers. Its scores is computed differently from the other components: it is the difference between the maximum and minimum correctness score across all the topics of the knowledge base.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=78.78787878787878 class=" progress-green ">78.79%</progress>
                    </div>
                </div>
                
                <div class="overall-card">
                    <div class="overall-title">Overall Correctness Score</div>
                    <div class="overall-value">48%</div>
                </div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">RECOMMENDATION</div>
                <span class="section-content">Focus on enhancing the Generator&#39;s effectiveness for complex questions, as this low score suggests it struggles with paraphrased queries, and ensure parity in performance across topics by improving the knowledge base regarding Pharmaceutical Labeling.</span>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">CORRECTNESS BY TOPIC</div>
                    <script type="text/javascript">
        (function() {
  const fn = function() {
    Bokeh.safely(function() {
      (function(root) {
        function embed_document(root) {
        const docs_json = '{"bc018fda-98a1-4681-8135-5414ab63f868":{"version":"3.4.3","title":"Bokeh Application","roots":[{"type":"object","name":"Figure","id":"p2460","attributes":{"height":350,"width_policy":"max","x_range":{"type":"object","name":"DataRange1d","id":"p2462","attributes":{"start":0}},"y_range":{"type":"object","name":"FactorRange","id":"p2469","attributes":{"factors":["Pharmaceutical Labeling","Tizanidine Hydrochloride"]}},"x_scale":{"type":"object","name":"LinearScale","id":"p2470"},"y_scale":{"type":"object","name":"CategoricalScale","id":"p2471"},"title":{"type":"object","name":"Title","id":"p2467","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p2489","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p2457","attributes":{"selected":{"type":"object","name":"Selection","id":"p2458","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p2459"},"data":{"type":"map","entries":[["correctness",{"type":"ndarray","array":{"type":"bytes","data":"uuiiiy66RkCqqqqqqqpQQA=="},"shape":[2],"dtype":"float64","order":"little"}],["metadata_values",["Pharmaceutical Labeling","Tizanidine Hydrochloride"]],["colors",["#a50026","#006837"]]]}}},"view":{"type":"object","name":"CDSView","id":"p2490","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p2491"}}},"glyph":{"type":"object","name":"HBar","id":"p2486","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"fill_color":{"type":"value","value":"#14191B"}}},"nonselection_glyph":{"type":"object","name":"HBar","id":"p2487","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"line_alpha":{"type":"value","value":0.1},"fill_color":{"type":"value","value":"#14191B"},"fill_alpha":{"type":"value","value":0.1},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"HBar","id":"p2488","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"#14191B"},"fill_alpha":{"type":"value","value":0.2},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p2498","attributes":{"data_source":{"id":"p2457"},"view":{"type":"object","name":"CDSView","id":"p2499","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p2500"}}},"glyph":{"type":"object","name":"HBar","id":"p2495","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"HBar","id":"p2496","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.1},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"HBar","id":"p2497","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.2},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p2508","attributes":{"visible":false,"data_source":{"type":"object","name":"ColumnDataSource","id":"p2502","attributes":{"selected":{"type":"object","name":"Selection","id":"p2503","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p2504"},"data":{"type":"map","entries":[["x",[0]],["y",[0]]]}}},"view":{"type":"object","name":"CDSView","id":"p2509","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p2510"}}},"glyph":{"type":"object","name":"Line","id":"p2505","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_width":2,"line_dash":[6]}},"nonselection_glyph":{"type":"object","name":"Line","id":"p2506","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_alpha":0.1,"line_width":2,"line_dash":[6]}},"muted_glyph":{"type":"object","name":"Line","id":"p2507","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_alpha":0.2,"line_width":2,"line_dash":[6]}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p2468","attributes":{"tools":[{"type":"object","name":"HoverTool","id":"p2482","attributes":{"renderers":"auto","tooltips":[["topic","@metadata_values"],["Correctness","@correctness{0.00}"]]}}]}},"toolbar_location":null,"left":[{"type":"object","name":"CategoricalAxis","id":"p2477","attributes":{"ticker":{"type":"object","name":"CategoricalTicker","id":"p2478"},"formatter":{"type":"object","name":"CategoricalTickFormatter","id":"p2479"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p2480"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p2472","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p2473","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p2474"},"axis_label":"Correctness (%)","axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p2475"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p2476","attributes":{"axis":{"id":"p2472"},"grid_line_color":"#E0E0E0","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p2481","attributes":{"dimension":1,"axis":{"id":"p2477"},"grid_line_color":"#E0E0E0","grid_line_alpha":0.25}},{"type":"object","name":"Span","id":"p2501","attributes":{"location":48.0,"dimension":"height","line_color":"#EA3829","line_width":2,"line_dash":[6]}},{"type":"object","name":"Legend","id":"p2511","attributes":{"border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p2512","attributes":{"label":{"type":"value","value":"Correctness on the entire Testset"},"renderers":[{"id":"p2508"}]}}]}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}]}}';
        const render_items = [{"docid":"bc018fda-98a1-4681-8135-5414ab63f868","roots":{"p2460":"d628670b-b073-4c97-aa18-4dee7cf75670"},"root_ids":["p2460"]}];
        root.Bokeh.embed.embed_items(docs_json, render_items);
        }
        if (root.Bokeh !== undefined) {
          embed_document(root);
        } else {
          let attempts = 0;
          const timer = setInterval(function(root) {
            if (root.Bokeh !== undefined) {
              clearInterval(timer);
              embed_document(root);
            } else {
              attempts++;
              if (attempts > 100) {
                clearInterval(timer);
                console.log("Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing");
              }
            }
          }, 10, root)
        }
      })(window);
    });
  };
  if (document.readyState != "loading") fn();
  else document.addEventListener("DOMContentLoaded", fn);
})();
    </script>

                <div id="d628670b-b073-4c97-aa18-4dee7cf75670" data-root-id="p2460" style="display: contents;"></div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">KNOWLEDGE BASE OVERVIEW</div>
                    <script type="text/javascript">
        (function() {
  const fn = function() {
    Bokeh.safely(function() {
      (function(root) {
        function embed_document(root) {
        const docs_json = '{"3efd4385-0120-457c-9504-ea852791fe20":{"version":"3.4.3","title":"Bokeh Application","roots":[{"type":"object","name":"Tabs","id":"p2391","attributes":{"sizing_mode":"stretch_width","tabs":[{"type":"object","name":"TabPanel","id":"p2321","attributes":{"title":"Topic exploration","child":{"type":"object","name":"Figure","id":"p2275","attributes":{"sizing_mode":"stretch_width","x_range":{"type":"object","name":"Range1d","id":"p2284","attributes":{"start":-15.26738133430481,"end":-3.4757434844970705}},"y_range":{"type":"object","name":"Range1d","id":"p2285","attributes":{"start":-0.2422795295715332,"end":10.272449612617493}},"x_scale":{"type":"object","name":"LinearScale","id":"p2286"},"y_scale":{"type":"object","name":"LinearScale","id":"p2287"},"title":{"type":"object","name":"Title","id":"p2282","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p2315","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p2272","attributes":{"selected":{"type":"object","name":"Selection","id":"p2273","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p2274"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"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"},"shape":[98],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"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"},"shape":[98],"dtype":"float32","order":"little"}],["topic",["Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Tizanidine Hydrochloride","Tizanidine Hydrochloride","Tizanidine Hydrochloride","Tizanidine Hydrochloride","Tizanidine Hydrochloride","Tizanidine Hydrochloride","Tizanidine Hydrochloride","Tizanidine Hydrochloride","Tizanidine Hydrochloride","Tizanidine Hydrochloride","Tizanidine Hydrochloride"]],["id",[0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99]],["content",["ADEA GARGLE- citric acid, sodium hydrogen carbonate, xylitol tablet, chewable \\n \\nK2resource co., ltd.\\nDisclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been\\napproved by FDA. \\nFor further information about unapproved drugs, click here.\\n----------\\nCITRIC ACID, SODIUM HYDROGEN CARBONATE, XYLITOL\\nFor oral care: Tooth whitening, removing bad breath, preventing tooth decay, preventing gingivitis and\\ntartar formation, plaque removal, oral cleansing\\nKeep...","K2resource co., ltd.\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:72191-0100\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nSODIUM BICARBONATE\\n (UNII: 8MDF5V39QO) \\n(SODIUM CATION -\\nUNII:LYR4M0NH37)\\nSODIUM\\nBICARBONATE\\n36.2 g  in 100 mg\\nXYLITOL\\n (UNII: VCQ006KQ1E) \\n(XYLITOL - UNII:VCQ006KQ1E)\\nXYLITOL\\n5 g  in 100 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\nMENTHOL\\n (UNII: L7T10EIP3A)\\n \\nProduct Characteristics\\nCo...","NUCYNTA - tapentadol hydrochloride tablet, film coated \\n \\nStat Rx USA\\n----------\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\nThese highlights do not include all the information needed to use NUCYNTA\\u2122 safely and effectively. See full\\nprescribing information for NUCYNTA\\u2122.\\n \\nNUCYNTA\\u2122 (tapentadol) immediate-release oral tablets    C-II\\nInitial U.S. Approval: 2008\\nRECENT MAJOR CHANGES\\nWarnings and Precautions (\\n5.4\\n)\\nJune 2009\\nINDICATIONS AND USAGE\\nNUCYNTA\\u2122 is an opioid analgesic indicated for the relief o...","USE IN SPECIFIC POPULATIONS\\nLabor and delivery: \\nshould not use during and immediately prior to labor and delivery. Monitor neonates, whose\\nmothers have been taking NUCYNTA\\u2122, for respiratory depression. (\\n8.2\\n)\\nNursing mothers: should not breast-feed. (\\n8.3\\n)\\nPediatric use: safety and effectiveness not established in patients less than 18 years of age. (\\n8.4\\n)\\nRenal or hepatic impairment: not recommended in patients with severe renal or hepatic impairment. Use with caution in\\npatients with moder...","8.7 Hepatic Impairment\\n9 DRUG ABUSE AND DEPENDENCE\\n9.1 Controlled Substance\\n9.2 Abuse\\n9.3 Dependence\\n10 OVERDOSAGE\\n10.1 Human Experience\\n10.2 Management of Overdose\\n11 DESCRIPTION\\n12 CLINICAL PHARMACOLOGY\\n12.1 Mechanism of Action\\n12.2 Pharmacodynamics\\n12.3 Pharmacokinetics\\n13 NON-CLINICAL TOXICOLOGY\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\n13.2 Animal Toxicology and/or Pharmacology\\n14 CLINICAL STUDIES\\n14.1 Orthopedic Surgery \\u2013 Bunionectomy\\n14.2 End-Stage Degenerative Joint Disea...","Daily doses greater than 700 mg on the first day of therapy and 600 mg on subsequent days have not\\nbeen studied and are not recommended.\\nNUCYNTA\\u2122 may be given with or without food \\n[see \\nClinical Pharmacology (12.3)\\n].\\n2.1 Renal Impairment\\nNo dosage adjustment is recommended in patients with mild or moderate renal impairment \\n[see \\nClinical\\nPharmacology (12.3)\\n]\\n.\\nNUCYNTA\\u2122 has not been studied in patients with severe renal impairment. The use in this population\\nis not recommended.\\n2.2 Hepatic Im...","which may result in adverse cardiovascular events \\n[see \\nDrug Interactions (7.4)\\n]\\n.\\n5 WARNINGS AND PRECAUTIONS\\n5.1 Respiratory Depression\\nRespiratory depression is the primary risk of mu-opioid agonists. Respiratory depression occurs more\\nfrequently in elderly or debilitated patients and in those suffering from conditions accompanied by\\nhypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may\\nsignificantly decrease pulmonary ventilation.\\nNUCYNTA\\u2122 should be ...","5.5 Driving and Operating Machinery\\nPatients should be cautioned that NUCYNTA\\u2122 may impair the mental and/or physical abilities required\\nfor the performance of potentially hazardous tasks such as driving a car or operating machinery. This is\\nto be expected especially at the beginning of treatment, at any change of dosage as well as in\\ncombination with alcohol or tranquilizers\\n [see \\nDrug Interactions (7.3)\\n]\\n.\\n5.6 Interactions with Alcohol and Drugs of Abuse\\nDue to its mu-opioid agonist activity,...","Because clinical studies are conducted under widely varying conditions, adverse event rates observed\\nin the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another\\ndrug and may not reflect the rates observed in clinical practice. A treatment-emergent adverse event\\nrefers to any untoward medical event associated with the use of the drug in humans, whether or not\\nconsidered drug-related.\\nBased on data from nine Phase 2/3 studies that administered multiple...","*\\nInfections and infestations\\n  Nasopharyngitis\\n1\\n&lt;1\\n  Upper respiratory tract infection\\n1\\n&lt;1\\n  Urinary tract infection\\n1\\n&lt;1\\nMetabolism and nutrition disorders\\n  Decreased appetite\\n2\\n0\\nMusculoskeletal and connective tissue\\ndisorders\\n  Arthralgia\\n1\\n&lt;1\\nNervous system disorders\\n  Dizziness\\n24\\n8\\n  Somnolence\\n15\\n3\\n  Tremor\\n1\\n&lt;1\\n  Lethargy\\n1\\n&lt;1\\nPsychiatric disorders\\n  Insomnia\\n2\\n&lt;1\\n  Confusional state\\n1\\n0\\n  Abnormal dreams\\n1\\n&lt;1\\n  Anxiety\\n1\\n&lt;1\\nSkin and subcutaneous tissue disorders\\n  Pruritus\\n5\\n1\\n  Hyp...","Psychiatric disorders:\\n euphoric mood, disorientation, restlessness, agitation, nervousness, thinking\\nabnormal\\nRenal and urinary disorders:\\n urinary hesitation, pollakiuria\\nRespiratory, thoracic and mediastinal disorders: \\noxygen saturation decreased, cough, dyspnea,\\nrespiratory depression\\nSkin and subcutaneous tissue disorders: \\nurticaria\\nVascular disorders:\\n blood pressure decreased\\nIn the pooled safety data, the overall incidence of adverse reactions increased with increased dose of\\nNUCYNTA\\u2122,...","Pregnancy Category C.\\nTapentadol HCl was evaluated for teratogenic effects in pregnant rats and rabbits following intravenous\\nand subcutaneous exposure during the period of embryofetal organogenesis. When tapentadol was\\nadministered twice daily by the subcutaneous route in rats at dose levels of 10, 20, or 40 mg/kg/day\\n[producing up to 1 times the plasma exposure at the maximum recommended human dose (MRHD) of\\n700 mg/day based on an area under the time-curve (AUC) comparison], no teratogenic eff...","as for younger adult patients with normal renal and hepatic function. Because elderly patients are more\\nlikely to have decreased renal and hepatic function, consideration should be given to starting elderly\\npatients with the lower range of recommended doses \\n[see \\nClinical Pharmacology (12.3)\\n]\\n.\\n8.6 Renal Impairment\\nIn patients with severe renal impairment, the safety and effectiveness of NUCYNTA\\u2122 has not been\\nestablished. NUCYNTA\\u2122 is not recommended in this population \\n[see \\nDosage and Adminis...","Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and\\nproper dispensing and storage are appropriate measures that help to limit abuse of drugs with mu-opioid\\nagonist properties.\\nInfants born to mothers physically dependent on opioids will also be physically dependent and may\\nexhibit respiratory difficulties and withdrawal symptoms \\n[see \\nWarnings and Precautions (5.1)\\n]\\n. Use of\\nNUCYNTA\\u2122 in this population has not been characterized. As NUCYNTA\\u2122 h...","intoxication with exceptionally large quantities. Before attempting gastrointestinal decontamination, care\\nshould be taken to secure the airway.\\n11 DESCRIPTION\\nNUCYNTA\\u2122 (tapentadol) Tablets are immediate-release film-coated tablets for oral administration.\\nThe chemical name is 3-[(1\\nR\\n,2\\nR\\n)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol\\nmonohydrochloride. The structural formula is:\\nThe molecular weight of tapentadol HCl is 257.80, and the molecular formula is C\\nH\\nNO\\u00b7HCl. The\\nn-octanol:water pa...","extensive first-pass metabolism. Maximum serum concentrations of tapentadol are typically observed at\\naround 1.25 hours after dosing.\\nDose-proportional increases in the C\\n and AUC values of tapentadol have been observed over the 50\\nto 150 mg dose range.\\nA multiple (every 6 hour) dose study with doses ranging from 75 to 175 mg tapentadol showed a mean\\naccumulation factor of 1.6 for the parent drug and 1.8 for the major metabolite tapentadol-O-\\nglucuronide, which are primarily determined by the do...","Pharmacokinetic Drug Interactions\\nTapentadol is mainly metabolized by Phase 2 glucuronidation, a high capacity/low affinity system,\\ntherefore, clinically relevant interactions caused by Phase 2 metabolism are unlikely to occur. Naproxen\\nand probenecid increased the AUC of tapentadol by 17% and 57%, respectively. These changes are not\\nconsidered clinically relevant and no change in dose is required.\\nNo changes in the pharmacokinetic parameters of tapentadol were observed when acetaminophen and\\nac...","14 CLINICAL STUDIES\\nThe efficacy and safety of NUCYNTA\\u2122 in the treatment of moderate to severe acute pain has been\\nestablished in two randomized, double-blind, placebo- and active-controlled studies of moderate to\\nsevere pain from first metatarsal bunionectomy and end-stage degenerative joint disease.\\n14.1 Orthopedic Surgery \\u2013 Bunionectomy\\nA randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study\\ndemonstrated the efficacy of 50 mg, 75 mg, and 100 mg NUCYNTA\\u2122...","50% or greater were significantly higher in patients treated with NUCYNTA\\u2122 at each dose versus\\nplacebo.\\n14.2 End-Stage Degenerative Joint Disease\\nA randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study\\nevaluated the efficacy and safety of 50 mg and 75 mg NUCYNTA\\u2122 given every 4 to 6 hours during\\nwaking hours for 10 days in patients aged 18 to 80 years, experiencing moderate to severe pain from\\nend stage degenerative joint disease of the hip or knee, defined...","The proportions of patients who showed reduction in pain intensity at 5 days of 30% or greater, or 50%\\nor greater were significantly higher in patients treated with NUCYNTA\\u2122 at each dose versus placebo.\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\nNUCYNTA\\u2122 Tablets are available in the following strengths and packages. All tablets are round and\\nbiconvex-shaped.\\n50 mg tablets are yellow and debossed with \\"O-M\\" on one side and \\"50\\" on the other side, and are\\navailable in bottles of 100 (NDC 50458-820-04) a...","Patients should be advised not to breast-feed an infant during treatment with NUCYNTA\\u2122 \\n[see \\nUse in\\nSpecific Populations (8.3)\\n]\\n.\\n17.6 Monoamine Oxidase Inhibitors\\nPatients should be informed not to take NUCYNTA\\u2122 while using any drugs that inhibit monoamine\\noxidase. Patients should not start any new medications while taking NUCYNTA\\u2122 until they are assured\\nby their healthcare provider that the new medication is not a monoamine oxidase inhibitor.\\n17.7 Seizures\\nPatients should be informed that NU...","you get a new prescription. There may be new information. This Medication Guide does not take\\nthe place of talking to your doctor about your medical condition or your treatment. Talk to your\\ndoctor if you have any questions.\\nWhat is the most important information I should know about NUCYNTA\\u2122?\\nNUCYNTA\\u2122 is a tablet that contains tapentadol, a strong medicine that is a pain medicine.\\nUse NUCYNTA\\u2122 exactly how your doctor tells you to. Do not use NUCYNTA\\u2122 if it has not been\\nprescribed for you.\\nYou sh...","Do not change the dose of NUCYNTA\\u2122 unless your doctor tells you to. \\nYour doctor may\\nchange your dose after seeing how the medicine affects you. Do not use NUCYNTA\\u2122 more often\\nthan prescribed. Call your doctor if your pain is not well controlled while taking NUCYNTA\\u2122.\\nFollow your doctor&#x27;s instructions about how to slowly stop taking NUCYNTA\\u2122 to help lessen\\nwithdrawal symptoms.\\nNUCYNTA\\u2122 can be taken with or without food.\\nWhat should I avoid while taking NUCYNTA\\u2122?\\nDo not drive, operate machinery, ...","Store NUCYNTA\\u2122 at 59\\u00baF to 86\\u00baF (15\\u00baC to 30\\u00baC). Keep NUCYNTA\\u2122 tablets dry.\\nDispose of NUCYNTA\\u2122 tablets you no longer need.\\nKeep NUCYNTA\\u2122 in a safe place out of the reach of children.\\nGeneral information about NUCYNTA\\u2122\\nMedicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not\\nuse NUCYNTA\\u2122 for a condition for which it was not prescribed. \\nDo not give NUCYNTA\\u2122 to other\\npeople, even if they have the same symptoms you have. Sharing NUCYNTA\\u2122 could be harmful\\n...","NUCYNTA 100MG PACKAGE LABEL\\n       \\n   \\n   \\n   \\n   \\n   \\n   \\nNUCYNTA  \\ntapentadol hydrochloride tablet, film coated\\nProduct Information\\nProduct Type\\nHUMAN\\nPRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:16590-\\n863(NDC:50458-820)\\nRoute of Administration\\nORAL\\nDEA Schedule\\nCII","Active Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\ntapentadol hydrochloride\\n (UNII: 71204KII53) \\n(tapentadol - UNII:H8A007M585)\\ntapentadol\\n50 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\ncellulose, microcrystalline\\n (UNII: OP1R32D61U)\\n \\nlactose monohydrate\\n (UNII: EWQ57Q8I5X)\\n \\ncroscarmellose sodium\\n (UNII: M28OL1HH48)\\n \\npovidone\\n (UNII: FZ989GH94E)\\n \\nmagnesium stearate\\n (UNII: 70097M6I30)\\n \\npolyvinyl alcohol\\n (UNII: 532B59J990)\\n \\ntitanium dioxide\\n (UNII: 15FIX9V2JP)\\n...","Stat Rx USA\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\ntapentadol hydrochloride\\n (UNII: 71204KII53) \\n(tapentadol - UNII:H8A007M585)\\ntapentadol\\n100 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\ncellulose, microcrystalline\\n (UNII: OP1R32D61U)\\n \\nlactose monohydrate\\n (UNII: EWQ57Q8I5X)\\n \\ncroscarmellose sodium\\n (UNII: M28OL1HH48)\\n \\npovidone\\n (UNII: FZ989GH94E)\\n \\nmagnesium stearate\\n (UNII: 70097M6I30)\\n \\npolyvinyl alcohol\\n (UNII: 532B59J990)\\n \\ntitanium dioxide\\n (UNII:...","GRX DYNE - povidone iodine solution \\n \\nGeritrex Corp.\\nDisclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they\\ncomply with applicable regulations and policies. FDA has not evaluated whether this product complies.\\n----------\\nGRx Dyne Solution\\nDrug Facts\\nActive Ingredient:                      Purpose\\nPovidone Iodine USP, 10% w/v  Antiseptic\\n(equivalent to 1% titratable Iodine)\\nUses\\nFirst aid antiseptic to help the risk of infection in \\nminor cuts, scra...","Citric acid, glycerin, Nonoxynol 10, purified water, sodium hydroxide\\nStore at room temperature: 15&#x27;-30&#x27;C (59&#x27;-86&#x27;F)\\nkeep out of reach of children. If swallowed get medical help \\nor contact a Poison Control Center right away.\\nEnter section text here\\nGRX DYNE  \\npovidone iodine solution\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:54162-269\\nRoute of Administration\\nTOPICAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nPOVIDONE-IODINE\\n (UNII: 85...","Geritrex Corp.\\nCITRIC ACID MONOHYDRATE\\n (UNII: 2968PHW8QP)\\n \\nGLYCERIN\\n (UNII: PDC6A3C0OX)\\n \\nNONOXYNOL-10\\n (UNII: K7O76887AP)\\n \\nWATER\\n (UNII: 059QF0KO0R)\\n \\nSODIUM HYDROXIDE\\n (UNII: 55X04QC32I)\\n \\nPackaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:54162-269-16\\n472 mL in 1 BOTTLE, PLASTIC\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nOTC monograph not final\\npart333A\\n05/16/2012\\nLabeler - \\n...","LISINOPRIL AND HYDROCHLOROTHIAZIDE- lisinopril and hydrochlorothiazide\\ntablets tablet \\n \\nCipla USA Inc.\\n----------\\nLisinopril and Hydrochlorothiazide Tablets, USP\\nRx Only\\nWARNING: FETAL TOXICITY\\nSee full prescribing information for complete boxed warning.\\nWhen pregnancy is detected, discontinue lisinopril and\\nhydrochlorothiazide tablets as soon as possible.\\nDrugs that act directly on the renin-angiotensin system can cause\\ninjury and death to the developing fetus. See \\nWarnings: Fetal Toxicity\\n.\\n...","Hydrochlorothiazide, USP is a white, or practically white, crystalline powder with a\\nmolecular weight of 297.72, which is slightly soluble in water, but freely soluble in sodium\\nhydroxide solution.\\nLisinopril and hydrochlorothiazide tablets, USP are available for oral use in three tablet\\ncombinations of lisinopril with hydrochlorothiazide: lisinopril and hydrochlorothiazide\\ntablets 10 mg/12.5 mg, containing 10 mg lisinopril and 12.5 mg hydrochlorothiazide,\\nlisinopril and hydrochlorothiazide tabl...","Concomitant administration of lisinopril and hydrochlorothiazide has little or no effect on\\nthe bioavailability of either drug. The combination tablet is bioequivalent to concomitant\\nadministration of the separate entities.\\nLisinopril\\nMechanism of Action\\n \\nLisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals.\\nACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the\\nvasoconstrictor substance, angiotensin II. Angiotensin II also stimulate...","state is prolonged. Older patients, on average, have (approximately doubled) higher\\nblood levels and area under the plasma concentration time curve (AUC) than younger\\npatients (see \\nDOSAGE AND ADMINISTRATION\\n). In a multiple dose pharmacokinetic study\\nin elderly versus young hypertensive patients using the lisinopril/hydrochlorothiazide\\ncombination, the AUC increased approximately 120% for lisinopril and approximately\\n80% for hydrochlorothiazide in older patients. Lisinopril can be removed by\\nhe...","accompanied by some loss of potassium and bicarbonate.\\nAfter oral use diuresis begins within two hours, peaks in about four hours and lasts\\nabout 6 to 12 hours.\\nHydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. When\\nplasma levels have been followed for at least 24 hours, the plasma half-life has been\\nobserved to vary between 5.6 and 14.8 hours. At least 61 percent of the oral dose is\\neliminated unchanged within 24 hours. Hydrochlorothiazide crosses the placental but...","the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused\\nagranulocytosis, particularly in patients with renal impairment or collagen vascular\\ndisease, and that available data are insufficient to show that lisinopril does not have a\\nsimilar risk (See \\nWARNINGS\\n).\\nIn considering the use of lisinopril and hydrochlorothiazide tablets, USP it should be\\nnoted that ACE inhibitors have been associated with a higher rate of angioedema in black\\nthan in nonblack patients (see \\nWARNIN...","Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of\\nrapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy or a neprilysin\\ninhibitor may be at increased risk for angioedema (see \\nPRECAUTIONS\\n).\\nIntestinal Angioedema:\\n Intestinal angioedema has been reported in patients treated\\nwith ACE inhibitors. These patients presented with abdominal pain (with or without\\nnausea or vomiting); in some cases there was no prior history of facial angioedema and\\nC-1...","myocardial infarction or cerebrovascular accident.\\nIf hypotension occurs, the patient should be placed in the supine position and, if\\nnecessary, receive an intravenous infusion of normal saline. A transient hypotensive\\nresponse is not a contraindication to further doses which usually can be given without\\ndifficulty once the blood pressure has increased after volume expansion.\\nLeukopenia/Neutropenia/Agranulocytosis:\\n Another angiotensin-converting enzyme\\ninhibitor, captopril, has been shown to ca...","rabbits. On a mg/kg basis, the doses used were up to 625 times (in mice), 188 times (in\\nrats), and 0.6 times (in rabbits) the maximum recommended human dose.\\nLisinopril and Hydrochlorothiazide\\nTeratogenicity studies were conducted in mice and rats with up to 90 mg/kg/day of\\nlisinopril (56 times the maximum recommended human dose) in combination with 10\\nmg/kg/day of hydrochlorothiazide (2.5 times the maximum recommended human dose).\\nMaternal or fetotoxic effects were not seen in mice with the com...","Lithium generally should not be given with thiazides (See PRECAUTIONS, Drug\\nInteractions, Lisinopril and Hydrochlorothiazide).\\nPRECAUTIONS\\nGeneral\\nLisinopril\\n \\nAortic Stenosis/Hypertrophic Cardiomyopathy:\\n As with all vasodilators, lisinopril\\nshould be given with caution to patients with obstruction in the outflow tract of the left\\nventricle.\\nImpaired Renal Function:\\n As a consequence of inhibiting the renin-angiotensin-\\naldosterone system, changes in renal function may be anticipated in suscept...","be due to this mechanism, it can be corrected by volume expansion.\\nHydrochlorothiazide\\n \\nPeriodic determination of serum electrolytes to detect possible electrolyte imbalance\\nshould be performed at appropriate intervals.\\nAll patients receiving thiazide therapy should be observed for clinical signs of fluid or\\nelectrolyte imbalance: namely, hyponatremia, hypochloremic alkalosis, and hypokalemia.\\nSerum and urine electrolyte determinations are particularly important when the patient is\\nvomiting exc...","therapy.\\nInformation for Patients\\nAngioedema:\\n Angioedema, including laryngeal edema may occur at any time during\\ntreatment with angiotensin-converting enzyme inhibitors, including lisinopril and\\nhydrochlorothiazide. Patients should be so advised and told to report immediately any\\nsigns or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips,\\ntongue, difficulty in swallowing or breathing) and to take no more drug until they have\\nconsulted with the prescribing physician.\\nSymp...","DOSAGE AND ADMINISTRATION\\n)\\nNon-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2\\nInhibitors (COX-2 Inhibitors):\\n \\nIn patients who are elderly, volume-depleted (including those on diuretic therapy), or\\nwith compromised renal function, co-administration of NSAIDs, including selective COX-2\\ninhibitors, with ACE inhibitors, including lisinopril, may result in deterioration of renal\\nfunction, including possible acute renal failure. These effects are usually reversible.\\nMonitor ...","mTOR (mammalian target of rapamycin) inhibitors\\n \\nPatients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g.,\\ntemsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema.\\n(see \\nWARNINGS\\n)\\nNeprilysin Inhibitors Patients taking concomitant neprilysin inhibitors may be at increased\\nrisk for angioedema. (see \\nWARNINGS\\n)\\nHydrochlorothiazide\\nWhen administered concurrently the following drugs may interact with thiazide diuretics.\\nAlcohol, barbiturates, or nar...","in vitro\\n alkaline elution rat hepatocyte assay. In addition, it did not produce increases in\\nchromosomal aberrations in an \\nin vitro\\n test in Chinese hamster ovary cells or in an \\nin\\nvivo\\n study in mouse bone marrow.\\nLisinopril\\n \\nThere was no evidence of a tumorigenic effect when lisinopril was administered for 105\\nweeks to male and female rats at doses up to 90 mg/kg/day (about 56 or 9 times* the\\nmaximum daily human dose, based on body weight and body surface area,\\nrespectively). There was no ...","Nursing Mothers\\nIt is not known whether lisinopril is excreted in human milk. However, milk of lactating\\nrats contains radioactivity following administration of \\nC lisinopril. In another study,\\nlisinopril was present in rat milk at levels similar to plasma levels in the dams. Thiazides\\ndo appear in human milk. Because of the potential for serious adverse reactions in\\nnursing infants from ACE inhibitors and hydrochlorothiazide, a decision should be made\\nwhether to discontinue nursing and/or disco...","adverse effects was required in 4.4% of patients principally because of dizziness, cough,\\nfatigue and muscle cramps.\\nAdverse experiences occurring in greater than one percent of patients treated with\\nlisinopril plus hydrochlorothiazide in controlled clinical trials are shown below.\\n                                                                         Percent of Patients in\\nControlled Studies\\n   Lisinopril and\\nHydrochlorothiazide\\n   (n=930)\\n   Incidence\\n(discontinuation)\\n   Placebo\\n   (n=207)\\n...","In rare cases, intestinal angioedema has been reported in post marketing experience.\\nHypotension:\\n In clinical trials, adverse effects relating to hypotension occurred as\\nfollows: hypotension (1.4%), orthostatic hypotension (0.5%), other orthostatic effects\\n(3.2%). In addition syncope occurred in 0.8% of patients (See \\nWARNINGS\\n).\\nCough:\\n See \\nPRECAUTIONS - Cough\\n.\\nClinical Laboratory Test Findings Serum Electrolytes:\\n (See \\nPRECAUTIONS\\n).\\nCreatinine, Blood Urea Nitrogen:\\n Minor reversible incre...","hallucinations; \\nRespiratory:\\n Malignant lung neoplasms, hemoptysis, pulmonary edema,\\npulmonary infiltrates, bronchospasm, asthma, pleural effusion, pneumonia, eosinophilic\\npneumonitis, wheezing, orthopnea, painful respiration, epistaxis, laryngitis, sinusitis,\\npharyngitis, rhinitis, rhinorrhea, chest sound abnormalities; \\nSkin:\\n Urticaria, alopecia,\\nherpes zoster, photosensitivity, skin lesions, skin infections, pemphigus, erythema,\\npsoriasis, rare cases of other severe skin reactions, includin...","Lisinopril\\n \\nFollowing a single oral dose of 20 g/kg no lethality occurred in rats and death occurred in\\none of 20 mice receiving the same dose. The most likely manifestation of overdosage\\nwould be hypotension, for which the usual treatment would be intravenous infusion of\\nnormal saline solution.\\nLisinopril can be removed by hemodialysis (see \\nWARNINGS, Anaphylactoid Reaction\\nDuring Membrane Exposure\\n).\\nHydrochlorothiazide\\n \\nOral administration of a single oral dose of 10 g/kg to mice and rats w...","possible, be discontinued for two to three days before beginning therapy with lisinopril\\nto reduce the likelihood of hypotension (See \\nWARNINGS\\n). If the patient\\u2019s blood pressure\\nis not controlled with lisinopril alone, diuretic therapy may be resumed.\\nIf the diuretic cannot be discontinued, an initial dose of 5 mg of lisinopril should be used\\nunder medical supervision for at least two hours and until blood pressure has stabilized\\nfor at least an additional hour (See \\nWARNINGS\\n and \\nPRECAUTIONS\\n...","Protect from excessive light and humidity.\\n*AN69 is a registered trademark of Hospal Ltd.\\nManufactured by:\\nInvaGen Pharmaceuticals, Inc.\\n(a subsidiary of Cipla Ltd.)\\nHauppauge, NY 11788\\nManufactured for:\\nCipla USA, Inc.\\n10 Independence Boulevard, Suite 300\\nWarren, NJ 07059\\nRevised: 10/2021\\nPACKAGE/LABEL PRINCIPAL DISPLAY PANEL \\u2013 10 mg/12.5 mg\\nNDC 69097-968-07                      Rx Only\\nLisinopril and\\nHydrochlorothiazide\\nTablets, USP\\n10 mg/12.5 mg\\n100 Tablets\\nCipla\\nNDC 69097-969-07             ...","Cipla\\nNDC 69097-971-07                      Rx Only\\nLisinopril and\\nHydrochlorothiazide\\nTablets, USP\\n20 mg/25 mg\\n100 Tablets\\nCipla\\nLISINOPRIL AND HYDROCHLOROTHIAZIDE  \\nlisinopril and hydrochlorothiazide tablets tablet","Product Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:69097-968\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nLISINOPRIL\\n (UNII: E7199S1YWR) \\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\nLISINOPRIL\\n10 mg\\nHYDROCHLOROTHIAZIDE\\n (UNII: 0J48LPH2TH) \\n(HYDROCHLOROTHIAZIDE -\\nUNII:0J48LPH2TH)\\nHYDROCHLOROTHIAZIDE\\n12.5 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\nANHYDROUS DIBASIC CALCIUM PHOSPHATE\\n (UNII: L11K75P92J)\\n \\nMAN...","lisinopril and hydrochlorothiazide tablets tablet\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:69097-969\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nLISINOPRIL\\n (UNII: E7199S1YWR) \\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\nLISINOPRIL\\n20 mg\\nHYDROCHLOROTHIAZIDE\\n (UNII: 0J48LPH2TH) \\n(HYDROCHLOROTHIAZIDE -\\nUNII:0J48LPH2TH)\\nHYDROCHLOROTHIAZIDE\\n12.5 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\nANHYDROUS D...","LISINOPRIL AND HYDROCHLOROTHIAZIDE  \\nlisinopril and hydrochlorothiazide tablets tablet\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:69097-971\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nLISINOPRIL\\n (UNII: E7199S1YWR) \\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\nLISINOPRIL\\n20 mg\\nHYDROCHLOROTHIAZIDE\\n (UNII: 0J48LPH2TH) \\n(HYDROCHLOROTHIAZIDE -\\nUNII:0J48LPH2TH)\\nHYDROCHLOROTHIAZIDE\\n25 mg\\nInactive Ingredients\\nI...","Cipla USA Inc.\\nLabeler - \\nCipla USA Inc. \\n(078719707)\\nEstablishment\\nName\\nAddress\\nID/FEI\\nBusiness Operations\\nInvaGen\\nPharmaceuticals, Inc\\n165104469\\nanalysis(69097-968, 69097-969, 69097-971) , manufacture(69097-968,\\n69097-969, 69097-971)\\nEstablishment\\nName\\nAddress\\nID/FEI\\nBusiness Operations\\nInvaGen Pharmaceuticals, Inc\\n080334903\\npack(69097-968, 69097-969, 69097-971)\\n \\nRevised: 11/2021","ALLERGY MULTI SYMPTOM- acetaminophen, chlorpheniramine maleate, and\\nphenylephrine hydrochloride tablet, coated \\n \\nMARC GLASSMAN, INC.\\n----------\\n1128B-MAR-2022-1005\\nDrug Facts\\nActive ingredients \\n(in each caplet)\\nPurpose\\nAcetaminophen 325 mg\\nPain reliever\\nChlorpheniramine maleate\\n2 mg\\nAntihistamine\\nPhenylephrine HCl 5 mg\\nNasal decongestant\\nUses\\ntemporarily relieves these symptoms of hay fever or other upper respiratory\\nallergies:\\nheadache\\nsinus congestion and pressure\\nnasal congestion\\nrunny nose...","If a skin reaction occurs, stop use and seek medical help right away.\\nDo not use\\nwith any other drug containing acetaminophen (prescription or nonprescription). If\\nyou are not sure whether a drug contains acetaminophen, ask a doctor or\\npharmacist.\\nif you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain\\ndrugs for depression, psychiatric or emotional conditions, or Parkinson&#x27;s disease), or\\nfor 2 weeks after stopping the MAOI drug. If you do not know if your prescription\\ndr...","800-222-1222). Quick medical attention is critical for adults as well as for children even if\\nyou do not notice any signs or symptoms.\\nDirections\\ndo not take more than directed (see \\noverdose warning\\n)\\nadults and\\nchildren 12\\nyears and over\\ntake 2 caplets every 4 hours\\nswallow whole; do not crush,\\nchew, or dissolve\\ndo not take more than 10 caplets\\nin 24 hours\\nchildren under \\n12 years\\nask a doctor\\nOther information\\nstore between 20\\u00b0-25\\u00b0C (68\\u00b0-77\\u00b0F) in a dry place\\nretain carton for complete product...","ALLERGY MULTI SYMPTOM  \\nacetaminophen, chlorpheniramine maleate, and phenylephrine hydrochloride tablet, coated\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:68998-228\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nCHLORPHENIRAMINE MALEATE\\n (UNII: V1Q0O9OJ9Z) \\n(CHLORPHENIRAMINE -\\nUNII:3U6IO1965U)\\nCHLORPHENIRAMINE\\nMALEATE\\n2 mg\\nPHENYLEPHRINE HYDROCHLORIDE\\n (UNII: 04JA59TNSJ) \\n(PHENYLEPHRINE -\\nUNII:1WS297W6MV)\\nPHENYLE...","MARC GLASSMAN, INC.\\nSILICON DIOXIDE\\n (UNII: ETJ7Z6XBU4)\\n \\nCROSCARMELLOSE SODIUM\\n (UNII: M28OL1HH48)\\n \\nFERRIC OXIDE YELLOW\\n (UNII: EX438O2MRT)\\n \\nMAGNESIUM STEARATE\\n (UNII: 70097M6I30)\\n \\nCROSPOVIDONE\\n (UNII: 2S7830E561)\\n \\nCELLULOSE, MICROCRYSTALLINE\\n (UNII: OP1R32D61U)\\n \\nPOLYETHYLENE GLYCOL, UNSPECIFIED\\n (UNII: 3WJQ0SDW1A)\\n \\nPOLYVINYL ALCOHOL, UNSPECIFIED\\n (UNII: 532B59J990)\\n \\nPOVIDONE, UNSPECIFIED\\n (UNII: FZ989GH94E)\\n \\nSTARCH, CORN\\n (UNII: O8232NY3SJ)\\n \\nPROPYLENE GLYCOL\\n (UNII: 6DC9Q167V3)\\n \\nSTEA...","CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE- candesartan cilexetil and\\nhydrochlorothiazide tablet \\n \\nANI Pharmaceuticals, Inc.\\n----------\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\nWARNING: \\nFETAL TOXICITY\\n\\u2022\\n\\u2022\\nDESCRIPTION\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP combine an angiotensin II receptor (type\\nAT\\n) antagonist and a diuretic, hydrochlorothiazide.\\nCandesartan cilexetil, a nonpeptide, is chemically described as (\\u00b1)-1-Hydroxyethyl 2-ethoxy-1-[\\np\\n-(\\no\\n-\\n1\\nH\\n...","Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of\\n297.72, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.\\nCandesartan cilexetil and hydrochlorothiazide tablets are available for oral administration in three tablet\\nstrengths of candesartan cilexetil and hydrochlorothiazide.\\nCandesartan cilexetil and hydrochlorothiazide tablets contain 16 mg or 32 mg of candesartan cilexetil\\nand 12.5 mg or 25 mg of hydrochloroth...","The mechanism of the antihypertensive effect of thiazides is unknown.\\nPharmacokinetics\\nGeneral\\nCandesartan Cilexetil\\nCandesartan cilexetil is rapidly and completely bioactivated by ester hydrolysis during absorption from\\nthe gastrointestinal tract to candesartan, a selective AT\\nsubtype angiotensin II receptor antagonist.\\nCandesartan is mainly excreted unchanged in urine and feces (via bile). \\nIt undergoes minor hepatic\\nmetabolism by O-deethylation to an inactive metabolite. \\nThe elimination half...","Geriatric\\nThe pharmacokinetics of candesartan have been studied in the elderly (\\u2265 65 years). \\nThe plasma\\nconcentration of candesartan was higher in the elderly (C\\n was approximately 50% higher, and AUC\\nwas approximately 80% higher) compared to younger subjects administered the same dose. \\nThe\\npharmacokinetics of candesartan were linear in the elderly, and candesartan and its inactive metabolite\\ndid not accumulate in the serum of these subjects upon repeated, once-daily administration. \\nNo initia...","plasma concentration of aldosterone was observed when 32 mg of candesartan cilexetil was\\nadministered to hypertensive patients. \\nIn spite of the effect of candesartan cilexetil on aldosterone\\nsecretion, very little effect on serum potassium was observed.\\nIn multiple-dose studies with hypertensive patients, there were no clinically significant changes in\\nmetabolic function including serum levels of total cholesterol, triglycerides, glucose, or uric acid. \\nIn a\\n12-week study of 161 patients with n...","in myocardial infarction and cardiovascular mortality also have been seen regularly.\\nElevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk\\nincrease per mmHg is greater at higher blood pressures, so that even modest reductions of severe\\nhypertension can provide substantial benefit. \\nRelative risk reduction from blood pressure reduction is\\nsimilar across populations with varying absolute risk, so the absolute benefit is greater in patients who\\nare at h...","candesartan cilexetil was 1 mg/kg/day (a maternally toxic dose that is about half the MRHD\\n). \\nIn each of\\nthese studies, hydrochlorothiazide was tested at the same dose level (10 mg/kg/day, about 4, 8, and 15\\ntimes the MRHD\\n in mouse, rats, and rabbit, respectively). \\nThere was no evidence of harm to the rat or\\nmouse fetus or embryo in studies in which hydrochlorothiazide was administered alone to the pregnant\\nrat or mouse at doses of up to 1000 and 3000 mg/kg/day, respectively.\\nThiazides cross ...","considered if the intraocular pressure remains uncontrolled. \\nRisk factors for developing acute angle-\\nclosure glaucoma may include a history of sulfonamide or penicillin allergy.\\nHypersensitivity Reaction\\nHypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of\\nallergy or bronchial asthma, but are more likely in patients with such a history.\\nPRECAUTIONS\\nMetabolic Disturbances\\nHydrochlorothiazide may alter glucose tolerance and raise serum levels of ch...","Interactions common to both Candesartan Cilexetil and Hydrochlorothiazide\\nNon-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)\\nIn patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised\\nrenal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II\\nreceptor antagonists, including candesartan, may result in deterioration of renal function, including\\npossible ac...","Cytotoxic products \\u2013 Thiazides may reduce the renal excretion of cytotoxic medicinal products (e.g.\\ncyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.\\nCyclosporine \\u2212 Concomitant treatment with cyclosporine may increase the risk of hyperuricemia and\\ngout-type complications.\\nCarcinogenesis, Mutagenesis, Impairment of Fertility\\nNo carcinogenicity studies have been conducted with the combination of candesartan cilexetil and\\nhydrochlorothiazide. \\nThere was no evidence of c...","Neonates with a history of in utero exposure to candesartan cilexetil and hydrochlorothiazide tablets:\\nIf oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion.\\nExchange transfusions or dialysis may be required as a means of reversing hypotension and/or\\nsubstituting for disordered renal function.\\nSafety and effectiveness in pediatric patients have not been established.\\nADVERSE REACTIONS\\nCandesartan Cilexetil and Hydrochlorothiazide\\nCandesartan cile...","melanoma skin cancer. In a study conducted in the Sentinel System, increased risk was predominantly for\\nsquamous cell carcinoma (SCC) and in white patients taking large cumulative doses. The increased risk\\nfor SCC in the overall population was approximately 1 additional case per 16,000 patients per year, and\\nfor white patients taking a cumulative dose of \\u226550,000 mg the risk increase was approximately 1\\nadditional SCC case for every 6,700 patients per year.\\nSkin:\\n \\nerythema multiforme including S...","Dose Titration by Clinical Effect: \\nA patient whose blood pressure is not controlled on 25 mg of\\nhydrochlorothiazide once daily can expect an incremental effect from candesartan cilexetil and\\nhydrochlorothiazide tablets 16 mg/12.5 mg. \\nA patient whose blood pressure is controlled on 25 mg of\\nhydrochlorothiazide but is experiencing decreases in serum potassium can expect the same or\\nincremental blood pressure effects from candesartan cilexetil and hydrochlorothiazide tablets 16\\nmg/12.5 mg and ser...","PRINCIPAL DISPLAY PANEL \\u2013 32 mg/12.5 mg\\nNDC 62559-661-90\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\n32 mg/12.5 mg\\nRx only\\n90 Tablets\\nPRINCIPAL DISPLAY PANEL \\u2013 32 mg/25 mg\\nNDC 62559-662-90\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\n32 mg/25 mg\\nRx only\\n90 Tablets","CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\ncandesartan cilexetil and hydrochlorothiazide tablet\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:62559-660\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nCANDESARTAN CILEXETIL\\n (UNII: R85M2X0D68) \\n(CANDESARTAN - UNII:S8Q36MD2XX)\\nCANDESARTAN\\nCILEXETIL\\n16 mg\\nHYDROCHLOROTHIAZIDE\\n (UNII: 0J48LPH2TH) \\n(HYDROCHLOROTHIAZIDE -\\nUNII:0J48LPH2TH)\\nHYDROCHLOROTHIAZIDE\\n1...","Flavor\\nImprint Code\\nACS\\nContains\\n    \\nPackaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:62559-660-90\\n90 \\nin 1 BOTTLE; Type 0: Not a Combination Product\\n09/26/2018\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nNDA authorized generic\\nNDA021093\\n09/26/2018\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\ncandesartan cilexetil and hydrochlorothiazide tablet\\nProduct Information\\nProduct Type...","Packaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:62559-661-90\\n90 \\nin 1 BOTTLE; Type 0: Not a Combination Product\\n09/26/2018\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nNDA authorized generic\\nNDA021093\\n09/26/2018\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\ncandesartan cilexetil and hydrochlorothiazide tablet\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (So...","ANI Pharmaceuticals, Inc.\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:62559-662-90\\n90 \\nin 1 BOTTLE; Type 0: Not a Combination Product\\n09/26/2018\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nNDA authorized generic\\nNDA021093\\n09/26/2018\\nLabeler - \\nANI Pharmaceuticals, Inc. \\n(145588013)\\n \\nRevised: 5/2020","CERTUS PVP-1 PREP SWABSTICK - povidone-iodine swab \\n \\nCertus Medical, Inc.\\nDisclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they\\ncomply with applicable regulations and policies. FDA has not evaluated whether this product complies.\\n----------\\nCertus PVP-1 Prep Swabstick 210012 Drug Facts and Label\\nDrug Facts Box OTC Active Ingredient Section\\nPovidone Iodine USP 10%\\nequivalent to 1% titratable iodine\\nDrug Facts Box OTC Purpose Section\\nAntiseptic\\nDrug...","Drug Facts Box OTC General Precautions Section\\nstore at room temperature 15\\n - 30\\n C (59\\n - 86\\n F)\\nDrug Facts Box OTC Inactive Ingredient Section\\ndisodium phosphate, glycerin, hydroxyethylcellulose, nonoxynol-10, dimethicone, water\\nCertus PVP-1 Prep Swabstick \\n210012 pouch\\n210012.jpg  Certus PVP-1 Prep Swabstick  pouch  \\n0\\n0\\n0\\n0","CERTUS PVP-1 PREP SWABSTICK  \\npovidone-iodine swab\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:75990-4019\\nRoute of Administration\\nTOPICAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nPOVIDONE-IODINE\\n (UNII: 85H0HZU99M) \\n(POVIDONE-IODINE - UNII:85H0HZU99M)\\nPOVIDONE-IODINE\\n0.1 mL  in 1 mL\\nInactive Ingredients\\nIngredient Name\\nStrength","Certus Medical, Inc.\\nWATER\\n (UNII: 059QF0KO0R)\\n \\nGLYCERIN\\n (UNII: PDC6A3C0OX)\\n \\nSODIUM PHOSPHATE, DIBASIC\\n (UNII: GR686LBA74)\\n \\nNONOXYNOL-10\\n (UNII: K7O76887AP)\\n \\nDIMETHICONE\\n (UNII: 92RU3N3Y1O)\\n \\nHYDROXYETHYL CELLULOSE (2000 CPS AT 1%)\\n (UNII: S38J6RZN16)\\n \\nPackaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:75990-4019-4\\n2 mL in 1 POUCH\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nOT...","ABALONE CRYSTALDOUBLE EX CC- niacinamide, adenosine, titanium dioxide, ethylhexyl\\nmethoxycinnamate cream \\n \\nC&amp;BCOSMETIC Co.,Ltd.\\nDisclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been\\napproved by FDA. \\nFor further information about unapproved drugs, click here.\\n----------\\nDrug Facts\\nNiacinamide, Adenosine, Titanium Dioxide, Ethylhexyl Methoxycinnamate\\nWater, Glycerin, Butylene Glycol, Etc\\nSkin Protectant - Anti-Wrinkle, Whitening, UV Protecting\\nk...","ABALONE CRYSTALDOUBLE EX CC  \\nniacinamide, adenosine, titanium dioxide, ethylhexyl methoxycinnamate cream\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:60611-0008\\nRoute of Administration\\nTOPICAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength","C&amp;BCOSMETIC Co.,Ltd.\\nNIACINAMIDE\\n (UNII: 25X51I8RD4) \\n(NIACINAMIDE - UNII:25X51I8RD4)\\nNIACINAMIDE\\n2 g  in 100 mL\\nTITANIUM DIOXIDE\\n (UNII: 15FIX9V2JP) \\n(TITANIUM DIOXIDE - UNII:15FIX9V2JP)\\nTITANIUM DIOXIDE\\n4.694 g  in 100 mL\\nADENOSINE\\n (UNII: K72T3FS567) \\n(ADENOSINE - UNII:K72T3FS567)\\nADENOSINE\\n0.04 g  in 100 mL\\nOCTINOXATE\\n (UNII: 4Y5P7MUD51) \\n(OCTINOXATE - UNII:4Y5P7MUD51)\\nOCTINOXATE\\n7 g  in 100 mL\\nInactive Ingredients\\nIngredient Name\\nStrength\\nWATER\\n (UNII: 059QF0KO0R)\\n \\nGLYCERIN\\n (UNII: PDC6A3C...","TIZANIDINE HYDROCHLORIDE- tizanidine hydrochloride capsule \\n \\nAdvagen Pharma Limited\\n----------\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\nThese highlights do not include all the information needed to use TIZANIDINE\\nHYDROCHLORIDE CAPSULES safely and effectively. See full prescribing information for\\nTIZANIDINE HYDROCHLORIDE CAPSULES. \\nTIZANIDINE HYDROCHLORIDE capsules, for oral use\\n \\nInitial U.S. Approval: 1996\\nINDICATIONS AND USAGE\\nTizanidine hydrochloride is a central alpha-2-adrenergic agonist indi...","Geriatric use: Tizanidine should be used with caution in elderly patients because clearance is decreased\\nfour-fold ( \\n8.5\\n)\\nSee 17 for PATIENT COUNSELING INFORMATION.\\nRevised: 9/2020\\nFULL PRESCRIBING INFORMATION: CONTENTS\\n*\\n1 INDICATIONS AND USAGE\\n2 DOSAGE AND ADMINISTRATION\\n2.1 Dosing Information\\n2.2 Dosing in Patients with Renal Impairment\\n2.3 Dosing in Patients with Hepatic Impairment\\n2.4 Drug Discontinuation\\n3 DOSAGE FORMS AND STRENGTHS\\n4 CONTRAINDICATIONS\\n5 WARNINGS AND PRECAUTIONS\\n5.1 Hypo...","12.1 Mechanism of Action\\n12.3 Pharmacokinetics\\n13 NONCLINICAL TOXICOLOGY\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\n14 CLINICAL STUDIES\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\n16.1 Tizanidine Hydrochloride Capsules\\n17 PATIENT COUNSELING INFORMATION\\n*\\nFULL PRESCRIBING INFORMATION\\n1 INDICATIONS AND USAGE\\nTizanidine hydrochloride is a central alpha-2-adrenergic agonist indicated for the\\nmanagement of spasticity. Because of the short duration of therapeutic effect,\\ntreatment with tizanid...","been studied.\\n2.2 Dosing in Patients with Renal Impairment\\nTizanidine hydrochloride capsules should be used with caution in patients with renal\\ninsufficiency (creatinine clearance &lt; 25 mL/min), as clearance is reduced by more than\\n50%. In these patients, during titration, the individual doses should be reduced. If higher\\ndoses are required, individual doses rather than dosing frequency should be increased\\n[see Warnings and Precautions ( \\n5.7\\n)] \\n.\\n2.3 Dosing in Patients with Hepatic Impairment\\nT...","Tizanidine is an \\u03b1 \\n-adrenergic agonist that can produce hypotension. Syncope has been\\nreported in the post marketing setting. The chance of significant hypotension may\\npossibly be minimized by titration of the dose and by focusing attention on signs and\\nsymptoms of hypotension prior to dose advancement. In addition, patients moving from\\na supine to fixed upright position may be at increased risk for hypotension and\\northostatic effects.\\nMonitor for hypotension when tizanidine is used in patients...","Clinical Pharmacology ( \\n12.3\\n)]\\n5.6 Hypersensitivity Reactions\\nTizanidine can cause anaphylaxis. Signs and symptoms including respiratory\\ncompromise, urticaria, and angioedema of the throat and tongue have been reported.\\nPatients should be informed of the signs and symptoms of severe allergic reactions and\\ninstructed to discontinue tizanidine and seek immediate medical care should these signs\\nand symptoms occur. \\n[see Contraindications ( \\n4\\n)]\\n5.7 Increased Risk of Adverse Reactions in Patients...","264 patients received tizanidine and 261 patients received placebo. Across the three\\nstudies patient ages ranged from 15\\u201369 years and 51.4 percent were women. The\\nmedian dose during the plateau phase ranged from 20\\u201328 mg/day.\\nThe most frequent adverse reactions reported in multiple dose, placebo-controlled\\nclinical studies involving 264 patients with spasticity were dry mouth,\\nsomnolence/sedation, asthenia (weakness, fatigue and/or tiredness) and dizziness.\\nThree-quarters of the patients rated t...","multiple sclerosis (Study 1) \\n[see Clinical Studies ( \\n14\\n)] \\n, the patients were specifically\\nasked if they had experienced any of the four most common adverse reactions: dry\\nmouth, somnolence (drowsiness), asthenia (weakness, fatigue and/or tiredness) and\\ndizziness. In addition, hypotension and bradycardia were observed. The occurrence of\\nthese reactions is summarized in \\nTable 2\\n. Other events were, in general, reported at a\\nrate of 2% or less.\\nTable 2: Single Dose, Placebo-Controlled Study -...","Paresthesia\\nRash\\nTremor\\n7 DRUG INTERACTIONS\\n7.1 Fluvoxamine\\nConcomitant use of fluvoxamine and tizanidine is contraindicated. Changes in\\npharmacokinetics of tizanidine when administered with fluvoxamine resulted in\\nsignificantly decreased blood pressure, increased drowsiness, and increased\\npsychomotor impairment. \\n[see Contraindications ( \\n4\\n) and Clinical Pharmacology ( \\n12.3\\n)]\\n7.2 Ciprofloxacin\\nConcomitant use of ciprofloxacin and tizanidine is contraindicated. Changes in\\npharmacokinetics of ...","12.3\\n)]\\n7.7 \\u03b1 \\n-adrenergic agonists\\nBecause hypotensive effects may be cumulative, it is not recommended that tizanidine\\nbe used with other \\u03b1 \\n-adrenergic agonists. \\n[see Warnings and Precautions ( \\n5.1\\n)]\\n8 USE IN SPECIFIC POPULATIONS\\n8.1 Pregnancy\\nPregnancy Category C\\nTizanidine has not been studied in pregnant women. Tizanidine should be given to\\npregnant women only if the benefit outweighs the risk to the unborn fetus.\\nReproduction studies performed in rats at a dose of 3 mg/kg, equal to the...","8.6 Impaired Renal Function\\nTizanidine is known to be substantially excreted by the kidney, and the risk of adverse\\nreactions to this drug may be greater in patients with impaired renal function. In patients\\nwith renal insufficiency (creatinine clearance &lt; 25 mL/min) clearance was reduced by\\nmore than 50%. In these patients, during titration, the individual doses should be\\nreduced. If higher doses are required, individual doses rather than dosing frequency\\nshould be increased. These patients sho..."]],["color",{"type":"ndarray","array":["#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8"],"shape":[98],"dtype":"object","order":"little"}]]}}},"view":{"type":"object","name":"CDSView","id":"p2316","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p2317"}}},"glyph":{"type":"object","name":"Scatter","id":"p2312","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.7},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p2313","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p2314","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.2}}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p2283","attributes":{"logo":"grey","tools":[{"type":"object","name":"HoverTool","id":"p2298","attributes":{"renderers":"auto","tooltips":"\\n    &lt;div style=\\"width:400px;\\"&gt;\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\n    &lt;b&gt;Document Content:&lt;/b&gt; @content\\n    &lt;/div&gt;\\n    "}},{"type":"object","name":"PanTool","id":"p2299"},{"type":"object","name":"WheelZoomTool","id":"p2300","attributes":{"renderers":"auto"}},{"type":"object","name":"BoxZoomTool","id":"p2301","attributes":{"overlay":{"type":"object","name":"BoxAnnotation","id":"p2302","attributes":{"syncable":false,"level":"overlay","visible":false,"left":{"type":"number","value":"nan"},"right":{"type":"number","value":"nan"},"top":{"type":"number","value":"nan"},"bottom":{"type":"number","value":"nan"},"left_units":"canvas","right_units":"canvas","top_units":"canvas","bottom_units":"canvas","line_color":"black","line_alpha":1.0,"line_width":2,"line_dash":[4,4],"fill_color":"lightgrey","fill_alpha":0.5}}}},{"type":"object","name":"ResetTool","id":"p2307"},{"type":"object","name":"SaveTool","id":"p2308"}]}},"left":[{"type":"object","name":"LinearAxis","id":"p2293","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p2294","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p2295"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p2296"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p2288","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p2289","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p2290"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p2291"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p2292","attributes":{"axis":{"id":"p2288"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p2297","attributes":{"dimension":1,"axis":{"id":"p2293"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Legend","id":"p2318","attributes":{"title":"Knowledge Base Tospics","title_text_color":"#B1B1B1","title_text_font_style":"bold","border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p2319","attributes":{"label":{"type":"value","value":"Pharmaceutical Labeling"},"renderers":[{"id":"p2315"}],"index":0}},{"type":"object","name":"LegendItem","id":"p2320","attributes":{"label":{"type":"value","value":"Tizanidine Hydrochloride"},"renderers":[{"id":"p2315"}],"index":87}}]}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}}},{"type":"object","name":"TabPanel","id":"p2390","attributes":{"title":"Failures","child":{"type":"object","name":"Figure","id":"p2326","attributes":{"sizing_mode":"stretch_width","x_range":{"type":"object","name":"Range1d","id":"p2335","attributes":{"start":-15.26738133430481,"end":-3.4757434844970705}},"y_range":{"type":"object","name":"Range1d","id":"p2336","attributes":{"start":-0.2422795295715332,"end":10.272449612617493}},"x_scale":{"type":"object","name":"LinearScale","id":"p2337"},"y_scale":{"type":"object","name":"LinearScale","id":"p2338"},"title":{"type":"object","name":"Title","id":"p2333","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p2365","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p2322","attributes":{"selected":{"type":"object","name":"Selection","id":"p2323","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p2324"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"m236wF60UcEyux3Bvp0gwQASY8HYi0TBMxAawX+NaMFObyjB+bwnwVC4KsGkbz/BFAIIwcILGMFVV1jBhT0XwRKj/sBSQBnB4itewYPOG8F4JUnBwbEgwbiEZMHpZSfBDnkywQ=="},"shape":[25],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"pg+1QF40MED9U6VAYUawQDBMOkDQ/hBAfY6JQI4wtUBo5YBAeOLqQIvrzkAmNB1AW7fIQMMq40CTsmRA3WHtQAIPuUC8vkxAJmuhQDap/UBg/DJA8gf0QEfZn0C7FJlAO3llQA=="},"shape":[25],"dtype":"float32","order":"little"}],["topic",["Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Tizanidine Hydrochloride","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Tizanidine Hydrochloride","Pharmaceutical Labeling","Pharmaceutical Labeling","Pharmaceutical Labeling","Tizanidine Hydrochloride","Pharmaceutical Labeling","Pharmaceutical Labeling"]],["correctness",[false,false,false,false,false,true,false,false,false,true,true,true,true,false,true,true,false,false,true,false,true,true,true,true,false]],["questions",["Considering the information provided, under what specific conditions or patient characteristics should the use of candesartan cilexetil and hydrochlorothiazide tablets be avoided, especially in relation to hypersensitivity and co-administration with other drugs?","Considering the clinical studies conducted on NUCYNTA\\u2122, what are the most frequently reported adverse events in patients, particularly those that were observed in at least 10% of any dosage group, and how do these compare to the placebo group in terms of percentage?","Could you identify the inactive components found in the lisinopril and hydrochlorothiazide tablet with the specific NDC code 69097-971, ensuring that your response only includes those ingredients that are not active and are unique to this particular formulation?","Considering the tablet with the NDC code 69097-971, what are the precise strengths of both lisinopril and hydrochlorothiazide, and how do these strengths compare to those in similar tablets with different NDC codes, if any?","Considering the lack of studies on NUCYNTA\\u2122 for individuals with severe hepatic impairment, what is the advised course of action for prescribing this medication to such patients, especially when considering potential risks and the absence of established safety and effectiveness?","Considering the detailed composition of NUCYNTA\\u2122, can you identify the primary pharmacological component responsible for its therapeutic effects, and ensure that your answer excludes any mention of the inactive ingredients?","Considering the strength of 32 mg of Candesartan Cilexetil and 12.5 mg of Hydrochlorothiazide, what are the color and shape of the tablet, and how does this compare to the tablet with a different strength of 25 mg of Hydrochlorothiazide?","In the context of a study on multiple sclerosis patients taking tizanidine, what are the four most frequently reported adverse reactions, considering only those reactions that were specifically inquired about by the researchers?","Under the condition that the item code is NDC:62559-662-90, can you specify the precise date when the marketing activities commenced for this particular product?","Under what specific circumstances might the concurrent administration of ACE inhibitors and mTOR inhibitors, such as temsirolimus, sirolimus, or everolimus, lead to an increased risk of developing angioedema, and what precautions should be considered to mitigate this risk?","Considering the available options, what are the specific tablet combinations of lisinopril and hydrochlorothiazide, including their dosages, that can be used for oral administration?","Considering the information provided in Document 24 about NUCYNTA 100MG, could you specify the method by which this medication is administered to patients?","What crucial information should be communicated to female patients of childbearing age who are on candesartan cilexetil and hydrochlorothiazide tablets, particularly regarding potential risks during pregnancy and any necessary actions they should take if they plan to become pregnant or discover they are pregnant?","Considering potential side effects, particularly those related to vision, what are the specific ocular complications associated with Hydrochlorothiazide, and under what conditions or time frame do these symptoms typically manifest?","What specific considerations and initial dosing precautions are recommended when administering NUCYNTA\\u2122 to elderly patients, especially in light of the potential for renal or hepatic impairments?","When monitoring patients on thiazide therapy, which specific electrolyte imbalances, such as hyponatremia, hypochloremic alkalosis, and hypokalemia, should be carefully observed, particularly in cases of excessive vomiting or when parenteral fluids are administered?","Considering the use of candesartan cilexetil and hydrochlorothiazide tablets in patients diagnosed with heart failure, what are the potential risks, specifically focusing on renal function and electrolyte imbalances, and how should these be managed during the initial treatment period?","Could you detail the primary components of ADEA GARGLE chewable tablets, ensuring to include only those ingredients that are explicitly mentioned in the context provided, and also consider any potential allergens?","Considering the pharmacokinetics of Tizanidine, particularly its clearance rate, why is it advised to exercise caution when prescribing this medication to elderly patients, and what specific risks does this present?","Considering the adverse effects of lisinopril combined with hydrochlorothiazide, which specific side effects are most frequently responsible for patients deciding to stop the medication, and what percentage of patients experience these effects leading to discontinuation?","What specific precautions should patients take when using NUCYNTA\\u2122 in relation to monoamine oxidase inhibitors, and what steps should they follow before starting any new medications while on NUCYNTA\\u2122?","In the context of a patient who is currently on ACE inhibitors and begins to exhibit symptoms such as jaundice or significantly elevated hepatic enzymes, what specific steps should be taken immediately, and what follow-up actions are recommended to ensure the patient&#x27;s safety?","Under what circumstances might the simultaneous use of tizanidine and fluvoxamine lead to adverse effects, and what specific reactions should be anticipated?","Could you specify the active ingredients and their respective strengths for the lisinopril and hydrochlorothiazide tablet identified by NDC code 69097-968, ensuring that you do not confuse it with other similar products listed in the provided context?","Could you specify the method by which ABALONE CRYSTALDOUBLE EX CC should be applied or administered, considering it contains niacinamide and titanium dioxide among other ingredients?"]],["agent_answer",["The use of candesartan cilexetil and hydrochlorothiazide tablets should be avoided in patients who have a known hypersensitivity to either of the active ingredients or to any other sulfonamide-derived medications. Additionally, caution should be exercised when co-administering these tablets with other drugs that may increase the risk of hyperkalemia, such as potassium-sparing diuretics, potassium supplements, or nonsteroidal anti-inflammatory drugs (NSAIDs). Patients with a history of gout or impaired kidney function should also be monitored closely when using this medication combination.","The most frequently reported adverse events in patients taking NUCYNTA\\u2122, particularly those that were observed in at least 10% of any dosage group, include nausea, constipation, dizziness, and somnolence. In comparison to the placebo group, these adverse events were reported at a higher percentage in the patients taking NUCYNTA\\u2122. This indicates that these side effects are more common in patients taking the medication compared to those taking a placebo. It is important for healthcare providers to monitor patients closely for these adverse events and manage them appropriately to ensure the safety and well-being of the patients.","Yes, the inactive components found in the lisinopril and hydrochlorothiazide tablet with the specific NDC code 69097-971 include microcrystalline cellulose, crospovidone, lactose anhydrous, magnesium stearate, and mannitol. These ingredients are not active and are unique to this particular formulation.","The tablet with the NDC code 69097-971 contains lisinopril 10 mg and hydrochlorothiazide 12.5 mg. This means that the precise strengths of lisinopril and hydrochlorothiazide in this tablet are 10 mg and 12.5 mg, respectively.\\n\\nWhen comparing these strengths to similar tablets with different NDC codes, it is important to consider the therapeutic equivalence and bioequivalence of the medications. Different tablets may have varying strengths of lisinopril and hydrochlorothiazide, but they are usually within a similar range to maintain their therapeutic effect.\\n\\nIt is always recommended to consult with a healthcare professional or pharmacist for specific information on different tablets and their strengths to ensure proper dosing and effectiveness of the medication.","The advised course of action for prescribing NUCYNTA\\u2122 to individuals with severe hepatic impairment would be to proceed with caution and carefully weigh the potential risks against the expected benefits. It is important to monitor these patients closely for any signs of adverse effects or drug interactions, as their impaired liver function may affect how the medication is metabolized and eliminated from the body. Additionally, it would be prudent to start at a lower dose and titrate up slowly, if necessary, while closely monitoring the patient&#x27;s response to treatment. Ultimately, the decision to prescribe NUCYNTA\\u2122 to individuals with severe hepatic impairment should be made on a case-by-case basis, taking into account the specific patient&#x27;s medical history, overall health status, and pain management needs, as well as consulting with a healthcare provider with experience in managing pain in this population.","The primary pharmacological component responsible for the therapeutic effects of NUCYNTA is tapentadol, which is a centrally-acting synthetic opioid analgesic.","The tablet containing 32 mg of Candesartan Cilexetil and 12.5 mg of Hydrochlorothiazide is typically pink and round in shape. This tablet is not the same as the tablet containing 25 mg of Hydrochlorothiazide, which is typically yellow and oval in shape.","The four most frequently reported adverse reactions among multiple sclerosis patients taking tizanidine, based on inquiries by the researchers, are likely to be:\\n\\n1. Drowsiness\\n2. Fatigue\\n3. Dry mouth\\n4. Weakness","I&#x27;m sorry, but as an AI, I do not have real-time access to specific product marketing information. I recommend contacting the manufacturer or brand of the product with the NDC:62559-662-90 item code to inquire about the precise date when marketing activities commenced for this particular product.","The concurrent administration of ACE inhibitors and mTOR inhibitors can lead to an increased risk of developing angioedema due to their combined effects on the renin-angiotensin-aldosterone system. ACE inhibitors can increase levels of bradykinin, a potent vasodilator that can cause angioedema when levels are elevated. mTOR inhibitors, such as temsirolimus, sirolimus, or everolimus, can also increase bradykinin levels, further exacerbating the risk of angioedema when combined with ACE inhibitors.\\n\\nTo mitigate this risk, precautions that should be considered include monitoring patients closely for symptoms of angioedema, such as swelling of the face, lips, or throat, difficulty breathing, or difficulty swallowing. If angioedema is suspected, prompt discontinuation of the mTOR inhibitor and/or ACE inhibitor and immediate medical attention should be sought. Alternative medications that do not affect the renin-angiotensin-aldosterone system may need to be considered for the treatment of the underlying conditions for which these medications were prescribed. Additionally, patients should be educated about the signs and symptoms of angioedema and advised to seek medical attention if they experience any concerning symptoms.","Some specific tablet combinations of lisinopril and hydrochlorothiazide for oral administration include:\\n\\n- Lisinopril 10 mg / Hydrochlorothiazide 12.5 mg\\n- Lisinopril 20 mg / Hydrochlorothiazide 12.5 mg\\n- Lisinopril 20 mg / Hydrochlorothiazide 25 mg\\n\\nThese combinations are commonly used for the treatment of hypertension and can vary based on the specific needs of the individual patient. It is important to consult with a healthcare provider to determine the appropriate dosage and combination for each patient.","NUCYNTA 100MG is administered to patients orally, as mentioned in Document 24.","Female patients of childbearing age who are on candesartan cilexetil and hydrochlorothiazide tablets should be informed that these medications are not recommended during pregnancy as they may cause harm to the developing fetus, particularly during the second and third trimesters. It is important for these patients to use effective contraception while taking these medications and to discuss alternative treatment options with their healthcare provider if they are planning to become pregnant or discover they are pregnant.\\n\\nIf a patient becomes pregnant while taking candesartan cilexetil and hydrochlorothiazide tablets, they should contact their healthcare provider immediately to discuss the potential risks to the fetus and to determine if alternative treatment options are necessary. It is important for patients to weigh the potential risks and benefits of continuing these medications during pregnancy and to follow their healthcare provider&#x27;s guidance closely.","Hydrochlorothiazide, a commonly prescribed diuretic, has been associated with several ocular complications, including acute angle-closure glaucoma, myopia, and non-arteritic anterior ischemic optic neuropathy (NAION).\\n\\nAcute angle-closure glaucoma is a serious side effect of Hydrochlorothiazide that can occur shortly after starting the medication. Symptoms include sudden onset of severe eye pain, blurred vision, halos around lights, and nausea or vomiting.\\n\\nMyopia, or nearsightedness, has also been reported in patients taking Hydrochlorothiazide. This condition may manifest gradually, with symptoms such as difficulty seeing objects at a distance and eye strain.\\n\\nNon-arteritic anterior ischemic optic neuropathy (NAION) is a rare but serious complication that has been associated with Hydrochlorothiazide use. This condition causes sudden vision loss, often in one eye, and is typically painless. The exact time frame for the manifestation of NAION is not well-defined, but it is typically reported within weeks to months of starting Hydrochlorothiazide.\\n\\nIt is important to seek immediate medical attention if any of these ocular complications occur while taking Hydrochlorothiazide, as prompt intervention may help prevent permanent vision loss. Consulting with a healthcare provider before starting or discontinuing any medication is recommended to minimize potential side effects.","When administering NUCYNTA\\u2122 to elderly patients, specific considerations and initial dosing precautions should be taken into account, especially in light of the potential for renal or hepatic impairments. \\n\\n1. Renal Impairments: Elderly patients are more likely to have decreased renal function, therefore, the dose of NUCYNTA\\u2122 should be adjusted according to the patient&#x27;s estimated creatinine clearance. Close monitoring of renal function is essential to ensure that the medication is being metabolized and eliminated properly.\\n\\n2. Hepatic Impairments: Elderly patients may also have reduced hepatic function, which can affect the metabolism and clearance of NUCYNTA\\u2122. Dosing adjustments may be necessary in patients with hepatic impairment to prevent adverse effects or toxicity. Liver function tests should be monitored regularly to assess the patient&#x27;s ability to metabolize the medication.\\n\\n3. Initial Dosing Precautions: When initiating NUCYNTA\\u2122 therapy in elderly patients, it is recommended to start with a lower initial dose and titrate carefully based on the patient&#x27;s response and tolerance. This gradual titration allows for better control of potential side effects and allows for the patient to adjust to the medication.\\n\\nOverall, it is important to consider the individual patient&#x27;s renal and hepatic function when prescribing NUCYNTA\\u2122 to elderly patients. Close monitoring and dose adjustments may be necessary to ensure the safe and effective use of the medication in this population.","When monitoring patients on thiazide therapy, it is important to carefully observe for electrolyte imbalances such as hyponatremia, hypochloremic alkalosis, and hypokalemia. This is especially important in cases of excessive vomiting or when parenteral fluids are administered because these conditions can exacerbate the risk of electrolyte imbalances. Electrolyte imbalances can have serious consequences for the patient&#x27;s health and must be promptly identified and corrected to prevent complications.","When using candesartan cilexetil and hydrochlorothiazide tablets in patients diagnosed with heart failure, there are potential risks related to renal function and electrolyte imbalances that need to be monitored and managed during the initial treatment period.\\n\\n1. Renal Function: Both candesartan cilexetil and hydrochlorothiazide can individually affect renal function. Candesartan can cause a decrease in renal function, particularly in patients with severe heart failure or those who are elderly. Hydrochlorothiazide can lead to electrolyte disturbances and dehydration, which can further impact renal function. Therefore, it is important to monitor renal function through regular blood tests, including serum creatinine levels, especially in patients with pre-existing renal impairment.\\n\\n2. Electrolyte Imbalances: Hydrochlorothiazide is a diuretic that can lead to electrolyte imbalances, such as hypokalemia (low potassium levels), hyponatremia (low sodium levels), and hypomagnesemia (low magnesium levels). These imbalances can potentially worsen heart failure symptoms and lead to adverse events. Monitoring electrolyte levels through regular blood tests is crucial during the initial treatment period. Additionally, patients should be advised on maintaining a diet rich in potassium and magnesium or may require supplementation under medical supervision.\\n\\nManagement during the initial treatment period should include close monitoring of renal function and electrolyte levels, particularly in high-risk patients. Dose adjustments may be necessary based on individual patient factors, and regular follow-up appointments should be scheduled to assess the patient&#x27;s response to treatment and any potential adverse effects. Education on the signs and symptoms of electrolyte imbalances should be provided to patients, and they should be advised to seek medical attention if they experience any concerning symptoms.\\n\\nOverall, in patients diagnosed with heart failure who are prescribed candesartan cilexetil and hydrochlorothiazide tablets, careful monitoring and proactive management of renal function and electrolyte imbalances are essential to ensure the safety and effectiveness of treatment.","The primary components of ADEA GARGLE chewable tablets, as explicitly mentioned in the provided context, include the following ingredients:\\n\\n- Glycerin\\n- Fumaric acid\\n- Xylitol\\n- Peppermint menthol flavoring\\n- Magnesium stearate\\n\\nPotential allergens that may be present in these ingredients include:\\n\\n- Xylitol (may cause gastrointestinal upset or allergic reactions in some individuals)\\n- Peppermint menthol flavoring (may cause sensitivities or allergic reactions in some individuals)","Tizanidine has a relatively low clearance rate, meaning it is cleared from the body at a slower rate compared to other medications. In elderly patients, who often have decreased renal and hepatic function, this slow clearance can lead to an accumulation of the medication in the body. This can result in an increased risk of side effects and toxicity from the drug.\\n\\nSome specific risks that elderly patients may face when taking Tizanidine include an increased likelihood of experiencing sedation, dizziness, and hypotension. These side effects can be more severe in elderly individuals due to age-related changes in metabolism and clearance of the medication. Additionally, elderly patients may be more sensitive to the effects of Tizanidine, increasing the risk of adverse reactions.\\n\\nTherefore, it is advised to exercise caution when prescribing Tizanidine to elderly patients and to carefully monitor their response to the medication. Dosing adjustments may be necessary to minimize the risk of side effects and toxicity in this population. Consulting with a healthcare provider and conducting regular follow-up assessments can help mitigate these risks and ensure the safe use of Tizanidine in elderly patients.","Common side effects of lisinopril combined with hydrochlorothiazide that may lead to patients discontinuation of the medication include dizziness, lightheadedness, electrolyte imbalances, hypotension, and kidney dysfunction. These side effects can be particularly troublesome for some individuals.\\n\\nIn a study examining the discontinuation rates of lisinopril combined with hydrochlorothiazide, it was found that approximately 10-15% of patients experience adverse effects leading to discontinuation. Out of these patients, the most frequently cited reasons for stopping the medication were dizziness and hypotension.\\n\\nOverall, dizziness and hypotension were the primary side effects responsible for patients deciding to stop lisinopril combined with hydrochlorothiazide, with approximately 5-8% of patients experiencing these effects leading to discontinuation.","Patients should take specific precautions when using NUCYNTA\\u2122 in relation to monoamine oxidase inhibitors (MAOIs) by avoiding concomitant use of NUCYNTA\\u2122 with MAOIs or within 14 days of discontinuing MAOIs. This is because the combination of NUCYNTA\\u2122 with MAOIs can result in serotonin syndrome, a potentially life-threatening condition characterized by agitation, hallucinations, coma, and death. Patients should also be cautious when using NUCYNTA\\u2122 with other serotonergic agents, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs), as this can also increase the risk of serotonin syndrome.\\n\\nBefore starting any new medications while on NUCYNTA\\u2122, patients should consult with their healthcare provider to ensure that the new medication does not interact with NUCYNTA\\u2122. It is important to provide a complete list of all medications, including prescription, over-the-counter, and herbal supplements, to the healthcare provider to avoid potential drug interactions. Patients should also be aware of the signs and symptoms of serotonin syndrome and seek medical attention immediately if they experience any concerning symptoms while taking NUCYNTA\\u2122 and a new medication.","If a patient on ACE inhibitors begins to exhibit symptoms such as jaundice or significantly elevated hepatic enzymes, it is important to take immediate action. The first step should be to discontinue the ACE inhibitors and consult with a healthcare provider. This may involve contacting the patient&#x27;s primary care physician, a specialist in hepatology or nephrology, or seeking care at an emergency department if the symptoms are severe.\\n\\nFollow-up actions may include conducting further testing to determine the cause of the symptoms, such as liver function tests, imaging studies, or a liver biopsy. It is important to monitor the patient closely for any worsening of symptoms and to ensure proper management of any underlying liver or kidney disease that may be contributing to the elevated enzymes. Depending on the severity of the symptoms and the underlying cause, additional treatments or interventions may be necessary to ensure the patient&#x27;s safety and well-being.","The simultaneous use of tizanidine and fluvoxamine can lead to adverse effects due to the potential for drug interactions. Tizanidine is a muscle relaxant commonly used to treat muscle spasms, while fluvoxamine is an antidepressant primarily used to treat obsessive-compulsive disorder and other psychiatric conditions. When taken together, fluvoxamine can increase the levels of tizanidine in the body, leading to an increased risk of side effects such as drowsiness, dizziness, and impaired cognitive function. In severe cases, this drug interaction can result in respiratory depression, hypotension, and even potentially life-threatening complications.\\n\\nSpecific reactions that can be anticipated when tizanidine and fluvoxamine are used together include increased sedation, dizziness, weakness, and difficulty concentrating. Patients may also experience confusion, blurred vision, and impaired motor coordination. It is important for healthcare providers to monitor patients closely when these medications are used concurrently and adjust the dosages as needed to minimize the risk of adverse effects. In some cases, alternative medications or treatment options may need to be considered to avoid potential drug interactions and ensure patient safety.","The lisinopril and hydrochlorothiazide tablet with NDC code 69097-968 contains 10 mg of lisinopril and 12.5 mg of hydrochlorothiazide as the active ingredients.","ABALONE CRYSTALDOUBLE EX CC should be applied to the skin as a cream or lotion. When applying, make sure to cleanse the skin first and then apply a thin, even layer of the product to the face or desired area. Gently massage the product into the skin until fully absorbed. As ABALONE CRYSTALDOUBLE EX CC contains niacinamide and titanium dioxide, it is important to apply sunscreen on top if using during the daytime, as titanium dioxide is a physical sunscreen ingredient that helps protect the skin from the sun&#x27;s harmful rays."]],["reference_answer",["Candesartan cilexetil and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to candesartan, to hydrochlorothiazide or to other sulfonamide-derived drugs, in patients with anuria, and should not be co-administered with aliskiren in patients with diabetes.","The most common adverse events reported by \\u226510% in any NUCYNTA\\u2122 dose group were nausea, dizziness, vomiting, and somnolence.","The inactive ingredients are anhydrous dibasic calcium phosphate, mannitol, starch, corn, magnesium stearate, ferric oxide yellow, and ferric oxide red.","Lisinopril 20 mg and Hydrochlorothiazide 25 mg","NUCYNTA\\u2122 has not been studied in patients with severe hepatic impairment, therefore, use of NUCYNTA\\u2122 is not recommended in this population.","The active ingredient in NUCYNTA\\u2122 is tapentadol.","The tablet is yellow and oval (biconvex) in shape.","The four most common adverse reactions reported are dry mouth, somnolence (drowsiness), asthenia (weakness, fatigue and/or tiredness), and dizziness.","The marketing start date for the product with item code NDC:62559-662-90 is 09/26/2018.","Patients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema.","Lisinopril and hydrochlorothiazide tablets are available in three combinations: 10 mg/12.5 mg, 20 mg/12.5 mg, and 20 mg/25 mg.","The route of administration for NUCYNTA 100MG is oral.","Female patients of childbearing age should be told about the consequences of exposure to candesartan cilexetil and hydrochlorothiazide tablets during pregnancy. Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible.","Hydrochlorothiazide can cause an idiosyncratic reaction resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation.","Care should be taken when selecting an initial dose for elderly patients.","Patients receiving thiazide therapy should be observed for clinical signs of fluid or electrolyte imbalance, namely, hyponatremia, hypochloremic alkalosis, and hypokalemia.","In patients with heart failure, candesartan cilexetil and hydrochlorothiazide tablets may cause excessive hypotension, which may lead to oliguria, azotemia, and (rarely) with acute renal failure and death.","The main ingredients in ADEA GARGLE chewable tablets are citric acid, sodium hydrogen carbonate, and xylitol.","Tizanidine should be used with caution in elderly patients because clearance is decreased four-fold.","The most common adverse effects leading to discontinuation are dizziness, cough, fatigue, and muscle cramps.","Patients should be informed not to take NUCYNTA\\u2122 while using any drugs that inhibit monoamine oxidase. Patients should not start any new medications while taking NUCYNTA\\u2122 until they are assured by their healthcare provider that the new medication is not a monoamine oxidase inhibitor.","Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.","Concomitant use of fluvoxamine and tizanidine is contraindicated due to changes in pharmacokinetics of tizanidine, resulting in significantly decreased blood pressure, increased drowsiness, and increased psychomotor impairment.","The active ingredients are Lisinopril with a strength of 10 mg and Hydrochlorothiazide with a strength of 12.5 mg.","TOPICAL"]],["id",[67,8,54,55,12,23,77,96,79,43,31,24,69,38,3,40,68,0,90,46,20,37,97,53,87]],["content",["in myocardial infarction and cardiovascular mortality also have been seen regularly.\\nElevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk\\nincrease per mmHg is greater at higher blood pressures, so that even modest reductions of severe\\nhypertension can provide substantial benefit. \\nRelative risk reduction from blood pressure reduction is\\nsimilar across populations with varying absolute risk, so the absolute benefit is greater in patients who\\nare at h...","Because clinical studies are conducted under widely varying conditions, adverse event rates observed\\nin the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another\\ndrug and may not reflect the rates observed in clinical practice. A treatment-emergent adverse event\\nrefers to any untoward medical event associated with the use of the drug in humans, whether or not\\nconsidered drug-related.\\nBased on data from nine Phase 2/3 studies that administered multiple...","lisinopril and hydrochlorothiazide tablets tablet\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:69097-969\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nLISINOPRIL\\n (UNII: E7199S1YWR) \\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\nLISINOPRIL\\n20 mg\\nHYDROCHLOROTHIAZIDE\\n (UNII: 0J48LPH2TH) \\n(HYDROCHLOROTHIAZIDE -\\nUNII:0J48LPH2TH)\\nHYDROCHLOROTHIAZIDE\\n12.5 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\nANHYDROUS D...","LISINOPRIL AND HYDROCHLOROTHIAZIDE  \\nlisinopril and hydrochlorothiazide tablets tablet\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:69097-971\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nLISINOPRIL\\n (UNII: E7199S1YWR) \\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\nLISINOPRIL\\n20 mg\\nHYDROCHLOROTHIAZIDE\\n (UNII: 0J48LPH2TH) \\n(HYDROCHLOROTHIAZIDE -\\nUNII:0J48LPH2TH)\\nHYDROCHLOROTHIAZIDE\\n25 mg\\nInactive Ingredients\\nI...","as for younger adult patients with normal renal and hepatic function. Because elderly patients are more\\nlikely to have decreased renal and hepatic function, consideration should be given to starting elderly\\npatients with the lower range of recommended doses \\n[see \\nClinical Pharmacology (12.3)\\n]\\n.\\n8.6 Renal Impairment\\nIn patients with severe renal impairment, the safety and effectiveness of NUCYNTA\\u2122 has not been\\nestablished. NUCYNTA\\u2122 is not recommended in this population \\n[see \\nDosage and Adminis...","Store NUCYNTA\\u2122 at 59\\u00baF to 86\\u00baF (15\\u00baC to 30\\u00baC). Keep NUCYNTA\\u2122 tablets dry.\\nDispose of NUCYNTA\\u2122 tablets you no longer need.\\nKeep NUCYNTA\\u2122 in a safe place out of the reach of children.\\nGeneral information about NUCYNTA\\u2122\\nMedicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not\\nuse NUCYNTA\\u2122 for a condition for which it was not prescribed. \\nDo not give NUCYNTA\\u2122 to other\\npeople, even if they have the same symptoms you have. Sharing NUCYNTA\\u2122 could be harmful\\n...","Flavor\\nImprint Code\\nACS\\nContains\\n    \\nPackaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:62559-660-90\\n90 \\nin 1 BOTTLE; Type 0: Not a Combination Product\\n09/26/2018\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nNDA authorized generic\\nNDA021093\\n09/26/2018\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\ncandesartan cilexetil and hydrochlorothiazide tablet\\nProduct Information\\nProduct Type...","multiple sclerosis (Study 1) \\n[see Clinical Studies ( \\n14\\n)] \\n, the patients were specifically\\nasked if they had experienced any of the four most common adverse reactions: dry\\nmouth, somnolence (drowsiness), asthenia (weakness, fatigue and/or tiredness) and\\ndizziness. In addition, hypotension and bradycardia were observed. The occurrence of\\nthese reactions is summarized in \\nTable 2\\n. Other events were, in general, reported at a\\nrate of 2% or less.\\nTable 2: Single Dose, Placebo-Controlled Study -...","ANI Pharmaceuticals, Inc.\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:62559-662-90\\n90 \\nin 1 BOTTLE; Type 0: Not a Combination Product\\n09/26/2018\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nNDA authorized generic\\nNDA021093\\n09/26/2018\\nLabeler - \\nANI Pharmaceuticals, Inc. \\n(145588013)\\n \\nRevised: 5/2020","mTOR (mammalian target of rapamycin) inhibitors\\n \\nPatients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g.,\\ntemsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema.\\n(see \\nWARNINGS\\n)\\nNeprilysin Inhibitors Patients taking concomitant neprilysin inhibitors may be at increased\\nrisk for angioedema. (see \\nWARNINGS\\n)\\nHydrochlorothiazide\\nWhen administered concurrently the following drugs may interact with thiazide diuretics.\\nAlcohol, barbiturates, or nar...","Hydrochlorothiazide, USP is a white, or practically white, crystalline powder with a\\nmolecular weight of 297.72, which is slightly soluble in water, but freely soluble in sodium\\nhydroxide solution.\\nLisinopril and hydrochlorothiazide tablets, USP are available for oral use in three tablet\\ncombinations of lisinopril with hydrochlorothiazide: lisinopril and hydrochlorothiazide\\ntablets 10 mg/12.5 mg, containing 10 mg lisinopril and 12.5 mg hydrochlorothiazide,\\nlisinopril and hydrochlorothiazide tabl...","NUCYNTA 100MG PACKAGE LABEL\\n       \\n   \\n   \\n   \\n   \\n   \\n   \\nNUCYNTA  \\ntapentadol hydrochloride tablet, film coated\\nProduct Information\\nProduct Type\\nHUMAN\\nPRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:16590-\\n863(NDC:50458-820)\\nRoute of Administration\\nORAL\\nDEA Schedule\\nCII","considered if the intraocular pressure remains uncontrolled. \\nRisk factors for developing acute angle-\\nclosure glaucoma may include a history of sulfonamide or penicillin allergy.\\nHypersensitivity Reaction\\nHypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of\\nallergy or bronchial asthma, but are more likely in patients with such a history.\\nPRECAUTIONS\\nMetabolic Disturbances\\nHydrochlorothiazide may alter glucose tolerance and raise serum levels of ch...","rabbits. On a mg/kg basis, the doses used were up to 625 times (in mice), 188 times (in\\nrats), and 0.6 times (in rabbits) the maximum recommended human dose.\\nLisinopril and Hydrochlorothiazide\\nTeratogenicity studies were conducted in mice and rats with up to 90 mg/kg/day of\\nlisinopril (56 times the maximum recommended human dose) in combination with 10\\nmg/kg/day of hydrochlorothiazide (2.5 times the maximum recommended human dose).\\nMaternal or fetotoxic effects were not seen in mice with the com...","USE IN SPECIFIC POPULATIONS\\nLabor and delivery: \\nshould not use during and immediately prior to labor and delivery. Monitor neonates, whose\\nmothers have been taking NUCYNTA\\u2122, for respiratory depression. (\\n8.2\\n)\\nNursing mothers: should not breast-feed. (\\n8.3\\n)\\nPediatric use: safety and effectiveness not established in patients less than 18 years of age. (\\n8.4\\n)\\nRenal or hepatic impairment: not recommended in patients with severe renal or hepatic impairment. Use with caution in\\npatients with moder...","be due to this mechanism, it can be corrected by volume expansion.\\nHydrochlorothiazide\\n \\nPeriodic determination of serum electrolytes to detect possible electrolyte imbalance\\nshould be performed at appropriate intervals.\\nAll patients receiving thiazide therapy should be observed for clinical signs of fluid or\\nelectrolyte imbalance: namely, hyponatremia, hypochloremic alkalosis, and hypokalemia.\\nSerum and urine electrolyte determinations are particularly important when the patient is\\nvomiting exc...","candesartan cilexetil was 1 mg/kg/day (a maternally toxic dose that is about half the MRHD\\n). \\nIn each of\\nthese studies, hydrochlorothiazide was tested at the same dose level (10 mg/kg/day, about 4, 8, and 15\\ntimes the MRHD\\n in mouse, rats, and rabbit, respectively). \\nThere was no evidence of harm to the rat or\\nmouse fetus or embryo in studies in which hydrochlorothiazide was administered alone to the pregnant\\nrat or mouse at doses of up to 1000 and 3000 mg/kg/day, respectively.\\nThiazides cross ...","ADEA GARGLE- citric acid, sodium hydrogen carbonate, xylitol tablet, chewable \\n \\nK2resource co., ltd.\\nDisclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been\\napproved by FDA. \\nFor further information about unapproved drugs, click here.\\n----------\\nCITRIC ACID, SODIUM HYDROGEN CARBONATE, XYLITOL\\nFor oral care: Tooth whitening, removing bad breath, preventing tooth decay, preventing gingivitis and\\ntartar formation, plaque removal, oral cleansing\\nKeep...","Geriatric use: Tizanidine should be used with caution in elderly patients because clearance is decreased\\nfour-fold ( \\n8.5\\n)\\nSee 17 for PATIENT COUNSELING INFORMATION.\\nRevised: 9/2020\\nFULL PRESCRIBING INFORMATION: CONTENTS\\n*\\n1 INDICATIONS AND USAGE\\n2 DOSAGE AND ADMINISTRATION\\n2.1 Dosing Information\\n2.2 Dosing in Patients with Renal Impairment\\n2.3 Dosing in Patients with Hepatic Impairment\\n2.4 Drug Discontinuation\\n3 DOSAGE FORMS AND STRENGTHS\\n4 CONTRAINDICATIONS\\n5 WARNINGS AND PRECAUTIONS\\n5.1 Hypo...","adverse effects was required in 4.4% of patients principally because of dizziness, cough,\\nfatigue and muscle cramps.\\nAdverse experiences occurring in greater than one percent of patients treated with\\nlisinopril plus hydrochlorothiazide in controlled clinical trials are shown below.\\n                                                                         Percent of Patients in\\nControlled Studies\\n   Lisinopril and\\nHydrochlorothiazide\\n   (n=930)\\n   Incidence\\n(discontinuation)\\n   Placebo\\n   (n=207)\\n...","Patients should be advised not to breast-feed an infant during treatment with NUCYNTA\\u2122 \\n[see \\nUse in\\nSpecific Populations (8.3)\\n]\\n.\\n17.6 Monoamine Oxidase Inhibitors\\nPatients should be informed not to take NUCYNTA\\u2122 while using any drugs that inhibit monoamine\\noxidase. Patients should not start any new medications while taking NUCYNTA\\u2122 until they are assured\\nby their healthcare provider that the new medication is not a monoamine oxidase inhibitor.\\n17.7 Seizures\\nPatients should be informed that NU...","myocardial infarction or cerebrovascular accident.\\nIf hypotension occurs, the patient should be placed in the supine position and, if\\nnecessary, receive an intravenous infusion of normal saline. A transient hypotensive\\nresponse is not a contraindication to further doses which usually can be given without\\ndifficulty once the blood pressure has increased after volume expansion.\\nLeukopenia/Neutropenia/Agranulocytosis:\\n Another angiotensin-converting enzyme\\ninhibitor, captopril, has been shown to ca...","Paresthesia\\nRash\\nTremor\\n7 DRUG INTERACTIONS\\n7.1 Fluvoxamine\\nConcomitant use of fluvoxamine and tizanidine is contraindicated. Changes in\\npharmacokinetics of tizanidine when administered with fluvoxamine resulted in\\nsignificantly decreased blood pressure, increased drowsiness, and increased\\npsychomotor impairment. \\n[see Contraindications ( \\n4\\n) and Clinical Pharmacology ( \\n12.3\\n)]\\n7.2 Ciprofloxacin\\nConcomitant use of ciprofloxacin and tizanidine is contraindicated. Changes in\\npharmacokinetics of ...","Product Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:69097-968\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nLISINOPRIL\\n (UNII: E7199S1YWR) \\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\nLISINOPRIL\\n10 mg\\nHYDROCHLOROTHIAZIDE\\n (UNII: 0J48LPH2TH) \\n(HYDROCHLOROTHIAZIDE -\\nUNII:0J48LPH2TH)\\nHYDROCHLOROTHIAZIDE\\n12.5 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\nANHYDROUS DIBASIC CALCIUM PHOSPHATE\\n (UNII: L11K75P92J)\\n \\nMAN...","ABALONE CRYSTALDOUBLE EX CC  \\nniacinamide, adenosine, titanium dioxide, ethylhexyl methoxycinnamate cream\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:60611-0008\\nRoute of Administration\\nTOPICAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength"]],["color",["#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#0a980a","#ba0e0e","#ba0e0e","#ba0e0e","#0a980a","#0a980a","#0a980a","#0a980a","#ba0e0e","#0a980a","#0a980a","#ba0e0e","#ba0e0e","#0a980a","#ba0e0e","#0a980a","#0a980a","#0a980a","#0a980a","#ba0e0e"]]]}}},"view":{"type":"object","name":"CDSView","id":"p2366","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p2367"}}},"glyph":{"type":"object","name":"Scatter","id":"p2362","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.7},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p2363","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p2364","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p2380","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p2371","attributes":{"selected":{"type":"object","name":"Selection","id":"p2372","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p2373"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"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"},"shape":[98],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"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"},"shape":[98],"dtype":"float32","order":"little"}]]}}},"view":{"type":"object","name":"CDSView","id":"p2381","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p2382"}}},"glyph":{"type":"object","name":"Scatter","id":"p2377","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.2}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p2378","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.1},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p2379","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.2}}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p2334","attributes":{"logo":"grey","tools":[{"type":"object","name":"PanTool","id":"p2349"},{"type":"object","name":"WheelZoomTool","id":"p2350","attributes":{"renderers":"auto"}},{"type":"object","name":"BoxZoomTool","id":"p2351","attributes":{"overlay":{"type":"object","name":"BoxAnnotation","id":"p2352","attributes":{"syncable":false,"level":"overlay","visible":false,"left":{"type":"number","value":"nan"},"right":{"type":"number","value":"nan"},"top":{"type":"number","value":"nan"},"bottom":{"type":"number","value":"nan"},"left_units":"canvas","right_units":"canvas","top_units":"canvas","bottom_units":"canvas","line_color":"black","line_alpha":1.0,"line_width":2,"line_dash":[4,4],"fill_color":"lightgrey","fill_alpha":0.5}}}},{"type":"object","name":"ResetTool","id":"p2357"},{"type":"object","name":"SaveTool","id":"p2358"},{"type":"object","name":"HoverTool","id":"p2325","attributes":{"renderers":[{"id":"p2365"}],"tooltips":"\\n    &lt;div style=\\"width:400px;\\"&gt;\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\n    &lt;b&gt;Question:&lt;/b&gt; @questions &lt;br&gt;\\n    &lt;b&gt;agent Answer:&lt;/b&gt; @agent_answer &lt;br&gt;\\n    &lt;b&gt;Reference Answer:&lt;/b&gt; @reference_answer &lt;br&gt;\\n    &lt;b&gt;Correctness:&lt;/b&gt; @correctness &lt;br&gt;\\n    &lt;b&gt;Content:&lt;/b&gt; @content\\n    &lt;/div&gt;\\n    "}}]}},"left":[{"type":"object","name":"LinearAxis","id":"p2344","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p2345","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p2346"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p2347"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p2339","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p2340","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p2341"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p2342"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p2343","attributes":{"axis":{"id":"p2339"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p2348","attributes":{"dimension":1,"axis":{"id":"p2344"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Legend","id":"p2368","attributes":{"title":"Question Correctness","title_text_color":"#B1B1B1","title_text_font_style":"bold","border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p2369","attributes":{"label":{"type":"value","value":"False"},"renderers":[{"id":"p2365"}],"index":0}},{"type":"object","name":"LegendItem","id":"p2370","attributes":{"label":{"type":"value","value":"True"},"renderers":[{"id":"p2365"}],"index":5}}]}},{"type":"object","name":"LabelSet","id":"p2386","attributes":{"level":"glyph","source":{"type":"object","name":"ColumnDataSource","id":"p2383","attributes":{"selected":{"type":"object","name":"Selection","id":"p2384","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p2385"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"mhwuwSnyYsE="},"shape":[2],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"muiTQIgRqEA="},"shape":[2],"dtype":"float32","order":"little"}],["topic",["Pharmaceutical Labeling","Tizanidine Hydrochloride"]]]}}},"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"text":{"type":"field","field":"topic"},"text_color":{"type":"value","value":"#B1B1B1"},"text_font_size":{"type":"value","value":"12pt"},"text_font_style":{"type":"value","value":"bold"},"text_align":{"type":"value","value":"center"}}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}}}],"tabs_location":"below"}}]}}';
        const render_items = [{"docid":"3efd4385-0120-457c-9504-ea852791fe20","roots":{"p2391":"c5700148-ac04-4bcc-8d6a-e5755a9e56e9"},"root_ids":["p2391"]}];
        root.Bokeh.embed.embed_items(docs_json, render_items);
        }
        if (root.Bokeh !== undefined) {
          embed_document(root);
        } else {
          let attempts = 0;
          const timer = setInterval(function(root) {
            if (root.Bokeh !== undefined) {
              clearInterval(timer);
              embed_document(root);
            } else {
              attempts++;
              if (attempts > 100) {
                clearInterval(timer);
                console.log("Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing");
              }
            }
          }, 10, root)
        }
      })(window);
    });
  };
  if (document.readyState != "loading") fn();
  else document.addEventListener("DOMContentLoaded", fn);
})();
    </script>

                <div id="c5700148-ac04-4bcc-8d6a-e5755a9e56e9" data-root-id="p2391" style="display: contents;"></div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">

                <div class="section-title">SELECTED METRICS</div>

                

            </div>
        </div>

        
    </div>
</div>



<script type="text/javascript">
    function opentab(evt, name) {
    // Declare all variables
    let i, tabcontent, tablinks;

    // Get all elements with class="tabcontent" and hide them
    tabcontent = document.getElementsByClassName("tabcontent");
    for (i = 0; i < tabcontent.length; i++) {
        tabcontent[i].style.display = "none";
    }

    // Get all elements with class="tablinks" and remove the class "active"
    tablinks = document.getElementsByClassName("tablinks");
    for (i = 0; i < tablinks.length; i++) {
        tablinks[i].className = tablinks[i].className.replace(" active", "");
    }

    // Show the current tab, and add an "active" class to the button that opened the tab
    document.getElementById(name).style.display = "block";
    evt.currentTarget.className += " active";
}
</script>
